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Phosphorylated myo-inositol compounds including inositol phosphates 
(InsPs) as well as the phosphatidylinositol polyphosphate lipids (PIPns) are 
critical biomolecules that regulate many of the most important biological 
processes and pathways. They are aberrant in many disease states due to their 
regulatory function. The same is true of the phospholipid phosphatidylserine (PS) 
which can serve as a marker to begin apoptosis. However, the full scope of 
activities of these structures is not clear, particularly since techniques that enable 
global detection and analysis of the production of these compounds spatially and 
temporally are lacking. With all of these obstacles in mind, devising a system that 
enables selective enrichment and detection of inositol and serine lipid products 
would allow the tracking of the various products formed during myo-inositol and 
serine metabolism and biological activity. Towards this end, the goal of this 
project is to design and synthesize azide-tagged myo-inositol precursors that 
enable the selective labeling and quantitation of inositol products via copper– 
mediated azide–alkyne (CuAAC) and strain–promoted (SPAAC) click chemistry, 
enrichment, mass spectrometry (MS) identification and fluorescence imaging. 
Successfully synthesized 2-propylazido inositol ether was the lead compound for 
these studies. The compound was incubated with and metabolically incorporated 
both into S. cerevisiae and C. albicans. Evidence of incorporation was proven by 
fluorescence microscopy after SPAAC conjugation to a dibenzocyclooctyne dye. 




validation and showed labeling of tagged inositol containing lipids in C. albicans. 
Also explored were serine precursors that can be used to irreversibly bind to the 
PS synthase active site in order to investigate the active site substrates and 
mechanism. Serine and cysteine synthesized with a bromopropyl chain tethered 
to the side chain thiol served as an electrophilic trap in the PS synthase active 
site. The modified cysteine compound has shown competition for active site 
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CHAPTER ONE : 
INTRODUCTION AND GENERAL INFORMATION 
1.1 Inositol and Inositol Metabolite Structure 
myo-Inositol is one of five naturally occurring inositol isomers (Figure 1-1). 
The meso form has a plane of symmetry through the molecule though each 
carbon contains defined stereochemistry (Figure 1-2). The other naturally 
occurring isomers are scyllo-inositol, neo-inositol, D-chiro-inositol and muco-
inositol. The four unnatural derivatives (Figure 1-2, blue text) are L-chiro-inositol, 
allo-inositol, epi-inositol, and cis-inositol.1-3 These isomers occur in smaller 
quantities than myo-inositol. Epimerization at one or two carbon atoms of the 
myo-configuration gives access to the other inositol derivatives.3-4  
 
 




The most sterically stable chair conformation of myo-inositol has five 
equatorial hydroxyls and one axial hydroxyl group. It is also known that ring flip of 
the chair is fairly common because the axial hydroxyl groups will hydrogen bond 
with each other (Figure 1-2).5-12 The axial position is named the 2-position for 
nomenclature purposes upon substitution or phosphorylation.2 This naming 
convention is useful in differentiating the inositol metabolites of interest, the 
phosphatidylinositol polyphosphates (PIPns) and the soluble inositol phosphates 
(InsPs). Substitution at certain positions of the myo-inositol backbone, specifically 
at the C-1/C-3 or C-4/C-6 carbon produces optically active products.2 
 
 
Figure 1-2. myo-Inositol numbering, plane of symmetry, and possible chair 
conformations. 
 
1.2 Inositol and its Biological Significance  
 Inositol is a carbohydrate of great biological importance. It is in a class of 
carbohydrates called cyclitols and bears hydroxyl groups at each of its six carbon 




hydroxyl groups each attached to a different carbon atom.13 The meso form, 
myo-inositol, is the one of greatest significance and understood as the primary 
biologically relevant inositol. It is found most often in nature as phytic acid or 
phytate salts. These phytates serve as inositol stores in the seed of fruits, 
especially in oranges and cantaloupes. Humans can synthesize myo-inositol de 
novo from glucose. Starting with glucose-6-phosphate (G-6-P), inositol-3-
phosphate synthase isomerizes G-6-P to myo-inositol-3-phosphate, which is 
dephosphorylated via inositol monophosphatase mostly found in human 
kidneys.13 This two-step process creates most of the free endogenous myo-
inositol used in humans. This sequence is also used in most living organisms in 
tandem with active transport to fulfill inositol requirements. 
 It is estimated that humans on average get about 1 g of inositol per day 
from their diet. Phytates and lecithins are contributors of masked inositols in 
various fruits, vegetables, grains, and seeds.13 Phytates contribute to total 
phosphate stores when separated from the core inositol structure via phytase 
enzymes. Inositol is also present in animal sources such as fish, poultry, meats, 
and dairy products in either the free form or as inositol phospholipids, specifically 
phosphatidylinositol. Inositol and its various metabolites have been implicated in 
various biological processes.13 They are primarily signaling and secondary 
messenger molecules that control processes such as cell growth14, 
carcinogenesis15, inflammation/immune response, insulin response and glucose 




neurological/brain function. Abnormalities in inositol and inositol metabolite 
production result in various diseases in the body that include diabetes, renal 
disorders, and cancer.20-21 
 Inositol is mainly produced in the kidneys, but it is found in many places in 
the body. The brain and the male reproductive system, which includes the testes 
and mammalian semen, have rich concentrations of free inositol. Inositol 
phospholipids are primarily localized in pancreas, heart, liver, and muscle. Equal 
amounts of free and phospholipid bound inositol are found in the intestines and 
blood plasma. Absorption of free inositol in the environment occurs through 
active transport. Uptake occurs against a concentration gradient in a Na+ and 
energy dependent manner.13 
 Inositol transporters are responsible for uptake and intracellular 
distribution of inositol in a variety of species. According to their transport 
mechanism, there are two classes of inositol transporters: Na+ coupled and 
proton coupled.22  Sodium/myo-inositol transporters (SMIT) were first identified in 
Madin–Darby canine kidney cells. The protein, first called SMIT and then 
changed to SMIT1 after a second transporter was found, was first characterized 
in Xenopus oocytes and showed strong similarity to Na+/glucose transporters.23  
SMIT1 has also been found in rats,24 humans,25 and mice.26 The preferred 
substrate is myo-inositol, but SMIT can also transport scyllo-inositol.27 SMIT2 




All proton–coupled inositol transporters belong to the Major Facilitator 
Superfamily.22 The first mammalian H+/ myo-inositol transporters (HMIT) from 
human and rat were identified in 2001 via an EST screen.29 Rat HMIT was 
analyzed with Xenopus oocytes and shown to be a HMIT symporter with a Km of 
100 μM. Competition experiments also showed that scyllo-, chiro-, and muco-
inositol were also transported by HMIT.22,29 Yeast proton–coupled inositol 
coupled transporters (ITR1 and ITR2) are located on the plasma membrane and 
accept myo-inositol with similar affinities.30 However, ITR1, present in both S. 
cerevisiae and C. albicans, appears to be responsible for the majority of inositol 
uptake as inositol transport is greatly attenuated when only ITR2 is present.30-31 
Transport activity is regulated by an inositol-dependent relocalisation of ITR1. 
Medium lacking inositol led to increased ITR1-GFP plasma membrane fusion, 
while inositol–rich media showed GFP redistribution with yeast cells.31  
This is important to note as any inositol probes that are used to study 
inositol metabolism likely will be ushered into the cell by these transporters first. 
While ITR1 in S. cerevisiae30 is very selective for myo-inositol, C. albicans shows 
the ability to transport a variety of natural and unnatural inositols as well as 
synthetic inositol derivatives and a myriad of sugars (Table 1).32 This is very 
advantageous as later proposed synthetic derivatives could likely be tolerated 
and transported by C. albicans better than in S. cerevisiae. There is also a 
possibility that synthetic inositol probes could perturb base transport 




Table 1. Proton–coupled inositol transporter substrate specificity.22 
























































































phospholipid synthesis so having access to a cell line with less substrate 
specificity will theoretically make cellular penetration easier.   
1.3 Inositol Lipid Biosynthesis, Regulation and Transport 
1.3.1 Phosphatidylinositol Polyphosphates (PIPns) and Inositol Phosphates 
(InsPs) General Structure  
 
 
Figure 1-3. PI general structure. 
 
The general structure of the PIPns is very straightforward and similar in 
structure to other glycerophospholipids. The traditional structure is composed of 
a myo-inositol head group linked at the 1-position to a phosphodiester moiety at 
the sn-3 position of a glycerophospholipid backbone.2 The typical 
glycerophospholipid backbone of PIPns in mammalian cells typically consists of a 
glycerol with a sn-1 linked stearic acid and a sn-2 linked arachidonic acid (Fig. 1-
3). This is a unique feature of PIPns compared to other phospholipids and their 




liver,34 bovine brain,33 and human platelets.13 Interestingly, non-mammalian cells 
do not show the same preference for this fatty acid configuration. Yeast cells 
show a preference for stearate and palmitate in the majority of its PIPns 
species.35 One mammalian cell type that also differs from conventional fatty acid 
enrichment is lamb liver PI preferring a monoenoic structure favoring stearic acid 
and oleic acid versus tetraenoic.36  
The head group inositol can be phosphorylated at different hydroxyl 
groups producing a total of seven unique, naturally existing structural isomers. 
The different combinations of phosphorylation occur at the 3-, 4-, and 5-positions 
producing a series of mono-, bis-, and trisphosphorylated species.2,13,19 Several 
abbreviations are used to identify these different isomers. The one that will be 
employed here, for example, will be PI(3,4,5)P3 to identify phosphatidylinositol 
(3,4,5)-trisphosphate. Using this naming convention and the possible isomer 
combinations, there can be three <PI(3,4,5)P3>,  two <PI(4,5)P2, PI(3,5)P2, and 
PI(3,4)P2>, or one <PI(3)P, PI(4)P, and PI(5)P> phosphate group(s) on the 
inositol headgroup in addition to the ubiquitous phosphodiester linkage.2 The 
non-phosphorylated base phospholipid is simply called PI.  
Inositol phosphates derive from the cleavage of the inositol headgroup 
PI(4,5)P2 by phospholipase C (Scheme 1-1). This releases Ins(1,4,5)P3 or IP3 
into the cytosol and leaves DAG, another important signaling molecule, behind in 
the cellular membrane.2,13,18-19 The three free hydroxyls can be further 




being the last two. Because of the defined stereochemistry at each carbon, there 
are 63 possible permutations of InsP structure.2  
 
 
Scheme 1-1. Inositol conversion into PIPns and InsPs. 
 
These derivatives can be further phosphorylated to produce another class 
of InsPs known as PP-InsPs/PP-IPs and [PP]2-InsPs or [PP]2-IPs. These 
derivatives contain one or two diphosphate groups usually found on the 1-, 3-, 
and/or 5-position.37-41 Structural elucidation was initially problematic due to the 
high energy nature of the pyrophosphate bond and the low concentrations found 
in mammalian cells. Slime molds in the genus Dictyostelium were used initially 
for structural validation since they produced PP-IPs in ~300–fold higher 
concentrations than mammalian cells.37,39 
1.3.2 Location and Regulation of PI Synthase, PIPns, and InsPs 
The myo-inositol metabolites have garnered considerable attention from 




starts with the enzyme PI synthase. This enzyme combines inositol with the 
liponucleotide CDP-DAG.42 The result of the reaction is PI and CMP due to the 
substitution of CMP for inositol on the glycerophospholipid backbone. The 
reverse reaction can happen as well in the presence of CMP which just 
reproduces the original inositol and CDP-DAG.43 The enzyme is membrane 
bound, and thought to act on the cytoplasmic face of the endoplasmic reticulum 
with the ability to mobilize to the plasma membrane.19,44 PI synthase regulation in 
both yeast and mammals is controlled by several mechanisms. Inositol 
concentration is pivotal to total phospholipid synthesis and it can be synthesized 
de novo utilizing myo-inositol phosphate synthase (MIPS) in both yeast45-48 and 
mammals (Figure 1-4).49 MIPS is encoded for by the INO1 gene which is the 
most heavily regulated gene in overall yeast phospholipid synthesis.50-51 PI 
synthase is encoded for by the PIS1 gene which has been shown to be an 
essential gene in S. cerevisiae due to PI being essential to growth and 
metabolism.45,52  
At the transcriptional level, many of the genes necessary for phospholipid 
synthesis are regulated by a sequence known as the upstream activating 
sequence (UAS), specifically UASINO.51 The basic pattern of UASINO–containing 
genes is as follows: the transcripts of the co-regulated genes of phospholipid 
biosynthesis are maximally expressed during logarithmic growth in media lacking 
inositol. If inositol is present in the growth medium, expression of these co- 









repression.54 Some of the genes that experience this type of repression include 
INO155 and CHO1,56 the latter of which encodes for PS synthase as well as 
genes encoding for CDP-DAG synthase,57 phospholipid N-methyltransferases,58 
and phosphatidylglycerophosphate (PGP) synthase.59 Transcriptional regulation 
of PIS1 is also regulated by zinc. Specifically, PIS1 is up regulated in zinc–
depletion conditions.60 In mammals, overexpression of PI synthase and CDP-
DAG synthase alone or in combination did not appreciably increase cellular 
content of, PI suggesting that inositol concentration may again be the major 
factor in PI production.61 Interestingly, C. albicans shares common features with 
both S.cerevisiae and mammalian PI synthase. The C. albicans PI synthase 
shows differences from the S. cerevisiae enzyme such as activation by bivalent 
cations like Mg2+ and Mn2+, inhibition by nucleotides, temperature optimum and 
activation energy, but also from the human PI synthase in preference for lipid 
substrates, inhibition by nucleoside monophosphates, and stabilization by Mn2+ 
and phospholipids.62  
PIPns are generally known for their activity as site-specific ligands that 
enforce binding of numerous peripheral proteins to membrane surfaces.19  Most 
of these target proteins reside in the cytosol and are recruited to the membrane 
via  various binding domains such as pleckstrin homology (PH),63 epsin NH2-
terminal homology (ENTH),64 and phox homology (PX)65 domains known to bind 
to PIPns. For example, class 1 phosphoinositide 3 kinases (PI3Ks) are recruited 




to phosphorylate PI(4,5)P2 to produce PI(3,4,5)P3 (Figure 1-5). PI(3,4,5)P3 is the 
head of a highly complex and sensitive signaling network mediating cellular 
growth functions such as proliferation, growth, and survival. Membrane 
translocation and activation of the PI(3,4,5)P3 target proteins initiate many local 
responses including assembly of signaling complexes and priming of protein 
kinase cascades.63,66 PI(3,4,5)P3 regulates a variety of PH type proteins such as 
a GDP/GTP exchange factor of ADP ribosylating factor 6 and protein tyrosine 
kinases of the Bruton’s tyrosine kinase (Btk) and Tec families.67-68 Two of the 
most important kinases are the serine threonine kinases Akt and PDK1 because 
of their aberrant activity in cancer.63,69  
Bound PDK1 along with another currently unknown kinase phosphorylates 
bound Akt at two specific serine and threonine residues, resulting in Akt 
activation. Activated Akt mediates cellular growth, proliferation, and survival 
signaling.66,70 The protein mTOR is another serine threonine kinase that serves 
as a molecular sensor that regulates protein synthesis based on available 
nutrients (Figure 1-5). It also regulates biogenesis by activating p70 S6 kinase, 
which enhances the translation of mRNA’s that have 5’ polypyrimidine tracts, and 
by inhibiting 4E-BP1, a translational repressor of mRNA’s that bear a 5’ CAP 
structure.66 mTOR is a direct phosphorylation target of activated Akt, though the 
specific mechanism of activation is currently unknown. However, it has been 









and LY294002 are associated with a decrease and reversal of muscle cell 
growth.66,72 In cell survival, Akt functions in an anti-apoptotic pathway. Dominant 
negative alleles of Akt survival mediated by IGF1 and constitutively active Akt 
rescue PTEN mediated apoptosis.73 The mechanism by which Akt prevents 
apoptosis is proposed to be multi-faceted because its phosphorylation of known 
apoptosis inducing proteins such as BAD,74 caspase-9,75 and FKHR15 all result in 
the negation of apoptosis in the affected cells (Figure 1-5). Akt is involved in cell 
proliferation by interfering in the CDK complexes and CDK inhibitors, which 
regulate the cell cycle. Akt directly phosphorylates cyclin D1 GSK3β, which 
blocks its kinase activity. Cyclin D1 is tagged for proteasome degradation by 
phosphorylation of GSK3β, but without that phosphorylation, cyclin D1 
accumulates in the cell, which stimulates further cell division.76 All of these 
factors contribute to the fact that Akt activation is one of the most important 
events that happens in the cell because of its link to carcinogenic activity. 
PI(4,5)P2 can also be cleaved by phospholipase C (Scheme 1-1), which 
results in the biosynthesis of the secondary messenger metabolites DAG and 
InsPs, e.g., inositol-(1,4,5)-trisphosphate ((Ins(1,4,5)P3), IP3).18,63,77 Once IP3 has 
been released into the cytosol, a myriad of kinases and phosphatases can 
transform it into one of thirty-five known InsPs (Scheme 1-1).2 Taking into 
account the different stereoisomers, the number of possible InsPs increases to 
sixty-three. The most well understood activity currently is with IP3. IP3 binds to its 




This release can affect a number of processes such as cell proliferation, 
secretion, and fertilization.17 Released calcium can also act as a mediator in 
protein binding or bridging of proteins and other ligands such as anionic 
phospholipids.2 The role of the ER is also dependent upon another inositol 
phosphate, inositol-(1,3,4,5)-tetrakisphosphate (Ins (1,3,4,5,)P4), IP4). IP4, in 
tandem with bound IP3, increases intracellular calcium absorption at low 
concentrations with extremely high specificity.78 Though IP3 is one of the most 
well understood InsPs, IP5 ((inositol-(1,3,4,5,6)-pentakisphosphate), 
Ins(1,3,4,5,6)P5) and IP6 ((inositol-(1,2,3,4,5,6)-hexakisphosphate), 
Ins(1,2,3,4,5,6)P6) are the most abundant in the cell. IP6 is also associated with 
calcium channel activation, but its range of activity has been extended to 
neurotransmission, protein regulation, immune responses,79 as well as 
antioxidant activity.21 IP5 also shows some activity in calcium channels80 as well 
as viral assembly,81 but the most interesting activity is associated with PI(4,5)P2 
and PI(3,4,5)P3 described above. IP5 can compete with those two PIPns for PH 
domain binding on PDK1,82 PTEN,83 and Akt.79,84-85 The binding of Akt attenuates 
angiogenesis causing cancer cells to undergo apoptosis. Because inositol-
containing biomolecules are linked to such important cellular signaling events, 
aberrant phosphoinositide activity is associated with disease states such as 






1.4 Targeting Inositol Metabolites 
 Developing a robust targeting system for tracking inositol metabolites is of 
significant interest due to their role in a myriad of cellular processes as 
mentioned previously. There are three ways to practically approach tracking 
these derivatives via bioengineering. The first way is tagging the fatty acid 
substituents of the glycerophospholipid backbone. This can be easily achieved 
by feeding the cells the appropriate tagged stearate or arachidonate to be 
bioengineered. Since these fatty acids are used in other biological processes 
involved in lipid production, this detail would have to be taken into account when 
determining the correct quantities to feed. This also decreases the specificity for 
just inositol metabolites. The second option is to directly tag the glycerol portion 
of the glycerophospholipid backbone. This substrate is also used in many other 
biological processes so specificity for inositol metabolites is attenuated again. 
The third and most effective option is to directly tag inositol. Tagging myo-inositol 
directly allows total tracking of both the PIPns and the InsPs, an advantage over 
the other two strategies because they deal with the glycerophospholipid 
backbone, which would be left as DAG in the membrane upon cleavage by 
phospholipase C. With this in mind, the next step is to decide what chemical tag 





1.4.1 Bioengineering myo-Inositol Metabolites Using Atomic Isotopes 
Isotopic labeling is a method that has been used frequently in labeling 
biologically relevant substances such as nucleic acids,87-92 proteins,93-96 and 
lipids.97-99 Specifically with myo-inositol, there have been several methods of 
radiolabeling incorporated to track downstream metabolite production. Since 
myo-inositol is comprised of only carbon, hydrogen and oxygen, the best 
isotopes to use would be 3H and 13C. Sahai and co-workers used 13C–labeled 
glucose and myo-inositol to confirm de novo synthesis of myo-inositol in L. 
donovani.100 They were able to successfully incorporate the radiolabeled myo-
inositol into PI, which was confirmed by MS. They also used MS to confirm the 
same peaks found for myo-inositol incorporation when radiolabeled glucose was 
incubated with these cells, thereby proving that L. donovani possesses the ability 
to produce myo-inositol in a similar manner as other organisms discussed 
previously. 
Radiolabeling is also useful for TLC separation of inositol phospholipids. 
Jones and co-workers developed a method to radiolabel phosphoinositide 
species in zebrafish using 32P isotopes to label the phosphodiester bond as well 
as the various sites of phosphorylation on the myo-inositol headgroup.99 This 
method represents a facile way to effectively label and separate 
phosphoinositides. The disadvantage of radiolabeling is the inability to visualize 
tagged substrates within cells, which is a great way to track substrate metabolism 




1.4.2 Bioengineering myo-Inositol Metabolites Using the Azide Tag  
The trinitrogen species known as azide has proven to be a powerful option 
for chemical tagging of biological metabolites. One of the attributes that makes it 
desirable is its small size, measuring out to 2.32 Å total. This makes it generally 
well tolerated by various enzyme active sites.101-105 Most organic azides are fairly 
inert unlike mineral azides such as sodium or lead azide that violently releases 
N2 upon detonation or shock.106 Installation of the azide moiety is facilitated in 
several ways. Azide is a pseudohalogen and nucleophile so it can participate in 
simple substitution chemistry via sodium azide and an appropriate leaving group. 
Another method of azide formation is diazo transfer using an amine. This can be 
accomplished with a variety of azide substrates with the end goal of transferring 
N2 to the amine.107 Another useful method for generating organic azides of 
varying carbon length is to install azide at one end of the carbon chain with a 
leaving group or alcohol at the other end to perform substitutions or Williamson 
ether synthesis reactions. In relation to myo-inositol, the best methods for azide 
installation are the first and third methods. Direct substitution of the hydroxyl 
groups would require double inversion in order to retain the original 
stereochemistry. Method three would produce an alkyl azidoether that could be 
used to customize linker length. 
As stated above, organic azide is fairly inert even though the terminal 
nitrogen has mild nucleophilic character. However, organic azide is very easily 




conversion is known as the Staudinger reduction, which was later refined to 
introduce an electrophilic trap on the TPP derivative (Figure 1-6). This 
modification became known as the Staudinger ligation since it ligates two 
molecules together.103,105,109 Another reaction that is azide specific and generally 
robust is the azide–alkyne cycloaddition (AAC).110 This reaction can be either 
CuAAC102,111 or SPAAC101 and has been called the “cream of the crop” of “click 
chemistry”.112 The end product is a triazole bearing the corresponding 
substituents from the azide and the alkyne. Both of the aforementioned reactions 
fall under the umbrella of azide–based bioorthogonal click chemistry, which will 
be discussed further ahead.  
 
 
Figure 1-6. Examples of azide based click chemistry including the 




1.4.3 Bioorthogonal Chemistry for Tagging Bioengineered Molecules 
Bioorthogonal chemistry is a term coined initially by Carolyn R. Bertozzi at 
the University of California–Berkeley (presently at Stanford University).109 The 
term refers to any chemical reaction that can selectively react with tagged 
substrates of interest while remaining inert to natural moieties in biological 
systems. These reactions must also have fast rates under physiological 
conditions as well as being unreactive toward the various functionalities found in 
vivo.109 The need for this kind of chemistry arose from the difficulty of studying 
biomolecules such as nucleic acids, lipids, and glycans in their native setting. 
Probing the roles, regulation, and production of these molecules is a 
considerable area of interest at the interface of chemistry and biology.  
Protein bioconjugation is the origin of bioorthogonal chemistry. Classic 
methods selectively target the side chains of the essential amino acids.113 
Cysteine and lysine are the most commonly modified residues using classic 
bioconjugation methodology along with some generated methods for tyrosine, 
glutamate, and histidine.113 Other methods used for protein bioconjugation 
include chemical modification of the N-terminus114-116 and native chemical 
ligation.117 True bioorthogonality arose when it was found that certain sequences 
of amino acids could be genetically encoded into proteins to produce suitable 
chemospecific interactions.118-121 This approach comes from the use of green 
fluorescent protein (GFP) and its ability to be bioengineered into proteins of 




cells and organisms.122-123 This is exploited in the use of fluorogenic 
bisarsenic119,121 and bisboronic acid124 reagents (Figure 1-7).  
Fluorgenic bisarsenic acid derivatives were synthesized to take advantage 
of cysteine–rich protein motifs that are selectively engineered in a CCXXCC 
manner where X can be any amino acid (AA) residue. The thiolates of the 
cysteine residues bind to the arsenic atoms present on the dye and modulate the 
fluorescence while selectively targeting that specific protein motif. The same 
strategy was used for bisboronic acid dyes. These dyes targeted serine rich 
motifs separated by proline and glycine residues. Boronic acid was chosen in 
particular due to its affinity for hydroxyl groups specifically in acting as molecular 
sensors for carbohydrates.125-128 All of these systems set the stage for the 
standard bioorthogonal reactions used today. 
 
 





Figure 1-8. Staudinger ligation of bioengineered azido sialic acid residues. 
 
The bioorthogonal reactions that will be discussed ahead in this section 
are the Staudinger ligation and AAC since they are specific to azides. Prior and 
recent work has demonstrated that metabolic labeling using azide–alkyne–
tagged substrates is an excellent tool for the analysis of important biomolecules 
in their native settings.102,109,111,129-131 Bertozzi and Saxon reported the synthesis 
of N-azidomannosamine for use in labeling modified sialic acid residues present 
on cell surfaces (Figure 1-8).105 Jurkat and HeLa cells were incubated with the 
peracetylated azido sugar precursor for three days and then treated with a 
modified triphenylphosphine derivative with an electrophilic trap. After treatment 
with fluorescein isothiocyanate, flow cytometry results showed a marked 




and those that were not. This experiment demonstrates the power of 
bioorthogonal chemistry. Since both azide and TPP are abiotic, the increased 
fluorescence in treated cells displays the chemoselectivity within biological 
systems.   
The Bertozzi group made a significant advancement in bioorthogonal 
chemistry with this work in azido sugars. This set the stage for other emergent 
labeling systems specifically in phospholipid labeling which is important to this 
work. Jao and co-workers describe in vivo labeling and fluorescence imaging of 
choline phospholipids131 through synthesis of alkynyl choline phospholipids 
(Figure 1-9). After incubation of propargylcholine with NIH 3T3 cells, the 
fluorescent dyes Alexa568 azide and fluorescein azide were used for staining 
and imaging utilizing CuAAC methodology. The results once again showed an 
increase in fluorescent membrane labelling in treated cells versus untreated cells 
proving again the robust chemical specificity of CuAAC and also showing that the 
small alkyne modification was well tolerated in vivo. 
 
 




In work that is most similar to the focus of this dissertation, Guo and 
coworkers synthesized azide–tagged inositols to be bioengineered in to 
glycosylphosphatidylinositols (GPIs) for detecting GPI anchored proteins.132 The 
ethyl azido linkers were attached to the 3-, 4-, and 5-O-positions on myo-inositol 
as ethers. Those positions were specifically targeted since the 1-, 2-, and 6-O-
positions are either linked to a phospholipid or glycan in GPIs or required for GPI 
biosynthesis. After incubation of these substrates in various cell types such as 
yeast and human cancer cells, incorporation of these tagged substrates was 
confirmed using CuAAC methodology. The cell surfaces were successfully 
stained using an alkyne dye and the GPI anchored proteins were successfully 
isolated using biotin/streptavidin western blotting. 
 
 





 Substrate labelling is a robust avenue to further elucidating specific 
mechanisms of metabolism in living systems. Specifically, the aim of work 
described in this dissertation is to synthesize tagged analogs of myo-inositol to 
further probe its role in cellular signaling processes. The above methods provide 
great proof of concept, particularly with the work of the Bertozzi lab. Since myo-
inositol is a fairly difficult molecule to work with due to its hydroxyl groups and its 
specific stereochemistry, methods for specific hydroxyl manipulation will have to 
be explored via protecting group synthesis. Previous work in inositol chemistry 
set the stage for the specific transformations needed to complete this work. 
1.5 Synthesis of myo-Inositol Derivatives 
 Synthetic routes for myo-inositol, its natural and synthetic stereoisomers, 
and synthetic derivatives are very well known. There are several strategies that 
can be used to access one or several inositol stereoisomers. The main chemical 
principles taken into account when designing these synthesis schemes are 
chirality and regioselectivity. Protecting groups play a huge part in these 
synthetic schemes since most of the reactions used are ubiquitous for 
carbohydrates. Synthetic schemes include approaches that begin with chiral 





1.5.1 From Chiral Sources 
There are a few different ways to produce inositol derivatives from chiral 
sources. Discussed ahead in this section will be approaches using the Ferrier-II 
rearrangement as well as inversion of naturally occurring methylated inositols. At 
its base, the Ferrier-II rearrangement is a metal-mediated rearrangement of enol 
ether pyrans, specifically of 5,6-unsaturated hexapyranose derivatives to 
cyclohexanones,133 which is useful in the preparation of enantiopure inositols 
including their amino and deoxy derivatives.1 Mercury salts, specifically 
mercury(II) chloride, are typically used for this reaction, but palladium is also a 
suitable metal as shown by Ikegami et al. (Scheme 1-2).134 
 
 
Scheme 1-2. Ferrier rearrangement to afford all possible inositol isomers.1 
 
They first synthesized isomeric acetyl aldehydes from protected methyl 
2,3,4-tri-O-benzylglycosides. After oxidation of the compounds, acetylation 




then subjected to a Pd(II)-mediated Ferrier-II reaction to afford chiral penta-
oxygenated cyclohexanones. Stereoselective reductions of the β-hydroxy 
ketones provided the inositol diastereomer precursors in good yield.  
 
 
Scheme 1-3. Inositol synthesis from L-quebrachitol.1 
 
Inositol phosphates can be made using an inversion approach on naturally 
occurring methylated inositols such as L-quebrachitol. Kozikowski et al.135 
developed a novel synthesis for PIPns by acetonide protection of four of the 
hydroxyl groups in L-quebrachitol (Scheme 1-3). Mesylation of the remaining 
hydroxyl group along with several protection and reprotection steps allowed the 
key step of oxidation and reduction to invert stereochemistry. This derivative 
eventually led to their target product. 
1.5.2 From Achiral Sources 
A reliable and efficient route for the synthesis of inositol analogues is the   
chemoenzymatic biooxidation of aromatic compounds.1 Hudlicky and co-workers 




including neo-inositol136 (Scheme 1-4) and some N- and O-linked inositol 
oligomers (Scheme 1-5).137-138 neo-Inositol was synthesized in seven steps by 
the enzymatic reduction of bromobenzene to the chiral diol 1-23. This derivative 
was acetonide protected and then reacted with 1,3-dibromo-5,5-
dimethylhydantoin in acetone/water. Epoxide formation and subsequent opening 
was facilitated with potassium hydroxide by going from room temperature to 




Scheme 1-4. Toluene oxygenase assisted synthesis of neo-inositol.1 
 
Key bromo-cis-diol intermediate 1-23 was reused for the synthesis of N- 
and O-linked inositol oligomers (Scheme 1-5). It was converted to the acetonide 
vinyl epoxide using dimethoxypropane with an acid followed by mCPBA. The 




resulted in the rapid cleavage of epoxide to the trans-amine, which was 
subjected to a coupling reaction of the vinyloxirane to yield the key oligomer 1-
30.1 Radical debromination followed by acetylation of the free hydroxyl groups 
formed the next intermediate 1-31, which was transformed into the acetonide–
protected cis-diol 1-32. Global deprotection afforded the target N- and O-linked 
inositol oligomers 1-33 and 1-34.  
 
 
Scheme 1-5. Synthesis of O- and N-linked inositol derivatives.1 
 
1.5.3 Regioselective Protection Strategies 
One method of producing inositol derivatives is to start with the base myo 
configuration and employ various regioselective protection strategies. The 
reactivity of the inositol hydroxyl groups is as follows: C1~C3 > C4 > C5.139 




preferred protecting groups for myo-inositol due to great reproducibility and yields 
(Scheme 1-6). Additionally, to produce separable inositol diastereomers, Bruzik 
and co-workers devised camphor ketal derivatives by using D-camphor with myo-
inositol in the presence of sulfuric acid.  
 
 
Scheme 1-6. Regioselective ketal protections of myo-inositol.53 
 
 144 Perhaps one of the best discoveries in regioselective myo-inositol 
protection was by Kishi and co-workers when the found that they could 
selectively protect the 1, 3, and 5 hydroxyls as the orthoformate derivatives.7 This 
allowed for the isolation of the C2 hydroxyl, which is important because 




cellular machinery.145-148 This was proven specifically by modifying this position 
with specific functionalities that introduce steric bulk via singular aromatic rings 
as well as alkyl–linked aromatic rings. 
 
 
Figure 1-11. Synthesis of 1,3,5-O-myo-inositol orthoformates.53 
 
myo-Inositol–based tetraols also showcase some regioselective character. 
Racemic 1,2-O-isopropylidene and cyclohexylidene inositols give 1,4,5- and 
1,4,6-O-trialkylated derivatives in a 1:1 ratio when subjected to dibutyltin oxide 
mediated alkylation conditions as mentioned above.141,149 Also, the C1/C3 
hydroxyl of the ketal derivative can be regioselectively silylated,150-151 
acylated,150,152-153 and phosphorylated154 proving that it is more reactive than the 
C4/C6 hydroxyl. 
Regioselective protection of myo-inositol triols is well known additionally. 
The equatorial C2 hydroxyl group has been silylated,7,155-156 acylated,11 
sulfonylated,10,12 and tritylated (Scheme 1-7).157 The C4 and C6 hydroxyls can 
also be regioselectively protected via acylation, sulfonylation, alkylation, and 




as metal hydrides tend to favor C4/C6 substitution while weak bases like pyridine 
favor C2 substitution. (1s)-Camphanoyl chloride has been used to desymmetrize 
the meso triols producing diastereomeric dicamphanoyl products (D and L). The 
symmetric 4,6-di-substituted alkyl and tosyl derivatives can be exclusively formed 
by using lithium hydride utilizing chelation control, base–promoted alkylation and 
tosylation (Scheme 1-8). This can also be done with sodium hydride, but there is 
a possibility of forming 2,4- and 2,6-di-substituted products using that reagent.  
 
 
Scheme 1-7. Regioselective monoprotection of inositol orthoformates.53 
 
 





1.5.4 Regioselective Deprotection Strategies 
Though relatively unexplored in comparison to selective protection, 
regioselective deprotection strategies are very useful in regenerating specific 
myo-inositol hydroxyls for further modification. Trans-ketals can be kinetically 
cleaved in the presence of cis-ketals either by acid–catalyzed hydrolysis or trans-
ketalization using ethylene glycol with catalytic p-toluene sulfonic acid (pTSA) 
(Scheme 1-9). Silver(I) oxide–mediated selective hydrolytic cleavage of the 
racemic 2,4-dibenzoate inositol orthoformate can be achieved preferentially at 
the C4 position over the C2 position. Subsequently, silver(I) oxide-based 
alkylation results in forming the symmetric 4,6-dialkyl-2-benzoate inositol 
orthoformate (Scheme 1-10).  
 
 





Scheme 1-10. Silver–mediated benzoyl group cleavage. 
 
1.6 Serine Structure and its Biological Significance 
 
 
Figure 1-12. L- and D-Serine. 
 
Serine has two structures, the natural occurring L-form and the D-form 
(Figure 1-12). It is an α-amino acid with a primary alcohol for its side chain 
substituent. It is one of the two amino acids bearing a side chain hydroxyl with 
the other being threonine. The structure is thought to be overall hydrophilic 
because of that hydroxyl group and its ability to hydrogen bond. The most 
common protein motifs involving serine are ST turns, ST motifs and ST 
staples.158 Serine is used in metabolism of fats, fatty acids, cell membranes, 
immune system function, and muscle growth. It can be synthesized either from 




deoxythymidine monophosphate.159 There is a class of enzymes known as serine 
proteases. These enzymes cleave peptide bonds in proteins where serine serves 
as the nucleophilic amino acid in the active site. These enzymes control 
biological functions such as digestion, blood coagulation, and reproduction.160 
1.7 Serine Lipid Biosynthesis, Regulation and Transport 
 Serine is also a constituent of native phospholipids. Phospholipids 
typically participate in the cell signaling system. Phosphatidylserine is a major 
component of the cell membrane and plays an integral role in the cell signaling 
system, specifically in apoptosis. Like other phospholipids, PS is tightly 
regulated, but it is unique in that it is the only phospholipid that has an amino acid 
within its structure. Also, its biosynthesis is regulated via two different pathways 
in prokaryotes and eukaryotes. Discussed ahead will be the PS general structure 
(Section 1.7.1), bacterial/yeast and mammalian PS synthesis (Section 1.7.2 and 
1.7.3), and the location and regulation of PS and PS synthase (Section 1.7.4).  
1.7.1 Phosphatidylserine (PS) General Structure 
PS follows the typical glycerophospholipid backbone structure. In 
mammalian cells the fatty acid content varies, but generally has highly 
unsaturated acyl chains in the lipid backbone often comprised of 1-stearoyl-2-
oleoyl and 1-stearoyl-2-arachidonoyl species in human plasma and 1-stearoyl-2-
docosahexaenoyl in brain matter.161 PS has three ionizable groups, the 




Because this phospholipid is acidic, it is a great chelator when in its salt form, 
specifically for calcium. This interaction changes the conformation of the head 
group, which can account for other downstream effects.162-164  
 
 
Figure 1-13. PS general structure. 
 
1.7.2 Bacterial and Yeast PS Synthesis 
Bacteria use the CDP-DAG pathway to synthesize PS.165 This pathway 
involves the use of CDP-DAG and serine to produce PS and CMP via PS 
synthase (Figure 1-14). This pathway is also a very important part of subsequent 
phosphatidylethanolamine (PE) synthesis. The structural gene for pssA is located 
at minute 56 on the E. coli chromosome.166 Structural homology of PS synthase 
indicates two different subclasses of the enzyme. Gram-negative bacteria have 
subclass I of the enzyme and gram-positive bacteria have sub class II, which 
correspond to the localization of the enzyme in the two types of bacteria.166-167 
In yeast PS is also synthesized via the CDP-DAG pathway. PS is a key 




phospholipids. PS decarboxylase converts PS into PE, which is then methylated 
to produce phosphatidylcholine (PC), the most abundant phospholipid present in 
yeast. Yeast cells that are defective in PS synthesis are also choline and 
ethanolamine auxotrophs.168-169 The gene CHO1 encodes for the production of 
PS synthase in S. cerevisiae.168 
 
 
Figure 1-14. Serine phospholipid metabolism in bacteria and yeast. 
 
 CHO1 recently has been established as a gene that confers virulence 
traits in the opportunistic fungus C. albicans. The Reynolds group has shown 
previously that a mutant Candida strain lacking the CHO1 gene becomes 
avirulent in mice models.170 This avirulence is characterized by defects in cell–
wall integrity, mitochondrial function, and filamentous growth as well as 
displaying ethanolamine auxotrophy. It also greatly attenuates the ability to mask 
β–(1-3)–glucan in the cell wall, which is essential to evading detection by host 
immune cells.171 PS decarboxylase mutants are also of great interest since they 




also resulted in decreased cell wall integrity, but it has slightly increased 
virulence and less severe cell wall defects compared to CHO1 deletion 
mutants.170 PS decarboxylase mutants also show variations in extracellular 
vesicle size, composition, and immunostimulatory properties compared to wt and 
CHO1 mutants.172 These deletions are appealing because CHO1 is conserved in 
fungi, but not in mammals since mammals synthesize PS from headgroup 
transfer of PC and PE.157, 169 This fact makes CHO1 and PS synthase exciting 
targets for anti-fungal treatments. 
1.7.3 Mammalian PS Synthesis 
 
 
Figure 1-15. PS synthesis in mammalian cells. 
 
PS is synthesized from PC and PE in mammalian cells. 
Phosphatidylserine synthase-1 is responsible for head group transfer of choline 
for serine, while phosphatidylserine synthase-2 is responsible for transfer of 




genes even though they have some similarities in sequence homologies. Studies 
in mice have shown that knockout of one of the genes does not affect cell 
viability, while knockout of both genes was embryonically lethal.173 Extensive 
investigation of the PS synthesis pathway in mammalian cells has shown that 
there is no analogous formation using CDP-DAG and serine like other 
phospholipid couplings.  
1.7.4 Location and Regulation of PS and PS Synthase 
 Bacterial PS synthesis is regulated by the presence of other phospholipids 
in the cell, specifically PG, PA, and cardiolipin.174-175 In yeast, PS synthase is an 
integral membrane protein whose activity is localized in the outer mitochondria 
and microsomes176 specifically in ER–associated structures called mitochondrial 
associated membranes (MAMs).161 Both bacterial and yeast PS synthase were 
examined further and found to be immunologically similar, which suggests that 
they are both encoded for by the CHO1 gene.177 It has been studied extensively 
and been found to be regulated predominantly in two ways, myo-inositol flux and 
phosphorylation events.54,178-179 Incubation of cells with inositol decreases 
production of the other major phospholipids including PS.45,48,54,180 
Phosphorylation of PS synthase via protein kinase A is also responsible for 
decreased enzymatic turnover of PS in vivo and in vitro.181 Another key metal 
implicated in PS synthase regulation is zinc.182 Zinc depletion in S. cerevisiae is 
associated with a 50% decrease in PS synthase activity as well as a 60% 




transcriptional regulation through the UASINO element of the PS synthase 
promoter.180,182 
 PS is a membrane lipid and found in most subcellular fractions of yeast. 
It’s most abundant in the plasma membrane where it makes up 34% of total 
phospholipid composition.161 This is markedly different from mammalian cells 
where PS has the greatest composition of 7.3% once again in the plasma 
membrane.183 Phospholipids are asymmetrically distributed across the 
membrane bilayer in eukaryotic cells. PS and PE are on the inner leaflet pointed 
towards the cytosol while PC and sphingomyelin are present on the outer 
leaflet.184 PS flippases are thought to be responsible for maintaining this 
asymmetric phospholipid distribution.161 PS is also transported to mitochondria 
via MAMs to be decarboxylated to PE. This transport occurs over several steps. 
After MAM synthesis, PS is transported to the mitochondrial outer membrane, 
ushered across the outer membrane to the inner membrane, and made available 
to PS decarboxylase in the inner membrane.185 
 PS is also important in signaling for apoptosis. As stated above, PS is 
predominantly found on the inner cell leaflet. In the early stages of apoptosis, PS 
is translocated to the outer leaflet of the phospholipid bilayer as a signal to be 
engulfed by macrophages. This was first observed in erythrocytes186 and then 
later seen in thymocytes that were treated with dexamethasone to induce 
apoptosis.187 Phagocytosis of apoptotic thymocytes was inhibited by using 




with liposomes composed of other anionic phospholipids or with phosphatidyl-D-
serine showing that macrophages involved in PS induced phagocytosis have 
substrate specificity.188 Activation of caspase 3189 causes PS to be presented on 
the outer membrane of cells,190 which is thought to come from a pool of newly 
synthesized PS.191-192 PS triggers phagocytosis through activating PS receptors 
on the macrophage directly or by binding bridging molecules such as MFG-E8, 
beta-2-glycoprotein 1 and annexins A1 and A2.193-196 
Annexins are a family of over 160 proteins that share the property of Ca2+-
dependent binding to anionic phospholipid surfaces.197 Specifically within the 
annexins is annexin A5, a protein with a high affinity for PS, which is the most 
efficient tool in demonstrating PS exposure in apoptotic cells. Fluorescent or 
radiolabeled annexin A5 allows detection of apoptotic cells in vitro and in vivo 
using a variety of imaging techniques and flow cytometry.198 Annexin A5 has 
been conjugated to or modified with radioactive isotopes of technetium,199-202 
iodine,203-205 fluorine,206 and indium207 for positron emission tomography (PET) 
imaging and scintigraphy (Figure 1-16). Green fluorescent protein208-209 and 
allophycocyanin (APC)210 have also been bioengineered into Annexin A5 as a 
way to study apoptosis at the cellular level. All of these techniques have provided 
robust ways to study mechanisms of PS regulated cellular processes.  
The literature review presented demonstrates the various methods 
employed in studying the biological significance of myo-inositol and serine. A 




roles that these two biomolecules play in crucial cellular processes. However, 
some questions remain unanswered. The first goal of this research is to develop 
novel azide tagged myo-inositol derivatives utilizing the synthetic techniques 
presented above. These molecules will be used for metabolic labeling studies in 
yeast to probe the mechanisms associated with downstream myo-inositol 
metabolite production. The second goal is to develop novel serine and cysteine 
derivatives with electrophilic traps to probe the AA composition and mechanism 
of headgroup transfer within the PS synthase active site.  
 
 






CHAPTER TWO : 
DESIGN AND SYNTHESIS OF AZIDE TAGGED MYO-INOSITOLS 
FOR CELLULAR BIOENGINEERING 
2.1 Design of myo-Inositol Analogs for Bioengineering 
Inositol metabolites including PIPns and InsPs are very important 
molecules in the regulation of cell signaling cascades. PIPns are generally minute 
constituents of the plasma membrane and are thus difficult to quantitate. InsPs 
are similar except they are found in the cytosol. These metabolites as well as the 
enzymes that regulate their production are critical to understanding complex 
mechanisms of cellular regulation and are thus tightly regulated. Creating a 
system for potential spatial and temporal resolution of these metabolites would 
be very advantageous in developing novel therapeutics for a plethora of diseases 
such as cancer, hypertension, and diabetes. Tagged myo-inositol analogues 
represent a robust way of tracking these metabolites in living systems. From the 
available literature, bioorthogonal click chemistry gives the most promising 
method for incorporation, tracking and detection (Figure 2-1). Inositol will be 
modified with these key elements in mind. It has also been observed that the 
position that presents the best opportunity for modification with minimal structural 
and enzymatic perturbation is the C2 position.2 Two novel myo-inositol 
derivatives bearing a propylazido ether at the C2 hydroxyl were successfully 
designed and synthesized to be bioengineered into inositol metabolites via native 




methyl group at the C2 carbon were designed and current synthetic progress is 
described. 
2.2 General Synthetic Outline 
 
 
Figure 2-1. Incorporation of azido–tagged myo-inositol into inositol 
metabolites with downstream click quantification. 
 
Targeting the C2 position gives the possibility of several azide tagging 
strategies. Each of these starts with a similar initial synthesis involving the 
regioselective isolation of that position for further modification. In the course of 
our studies, we have pursed three different strategies for introducing an azide tag 
at the 2-position. One of these is to replace the 2-hydroxyl group with azide using 
a double inversion nucleophilic substitution to retain the natural stereochemistry 
in the final product. In a second approach, we pursued a Williamson ether 
synthesis to introduce an azidoalkyl group onto the oxygen at the 2-position. 
Another feasible option we considered is to install azidomethyl group at C2 while 




are appealing due to the fact that there are inositol transporters in yeast that 
recognize some combinations of the 2, 3, 4, and 5-hydroxyls to bring inositol into 
the cell. Devising a system based on tagged inositol begins with synthesizing a 
suitable derivative, followed by feeding the derivative to cells, allowing the 
derivative to be bioengineered into cells, and then using click chemistry to 
quantify and visualize tagged metabolites. Synthetic progress towards the last 
two compounds will be discussed more ahead. 
2.3 Synthesis of 2-Azidopropyl Ether of myo-Inositol 
 
 
Scheme 2-1. Synthesis of 2-azidopropyl myo-inositol ethers. 
 
The main approach that we used for the labeling of myo-inositol is the 
second strategy described above, in which an alkylazide group was introduced 
using an ether linkage, as shown in probe 2-1 (Scheme 2-1). The synthesis of 




as the orthoformate to produce compound 2-3 as described by Kishi and co-
workers.7 This was later modified211 to also include subsequent selective 
dibenzylation of the 4- and 6-hydroxyls using lithium hydride as the metal hydride 
base. Previous studies have shown that sodium hydride was also able to 
produce the 4,6-dibenzyl compound, but these conditions also tend to yield 
traces of the 2,4/2,6 isomer as well.9-12,139,212 The reason for this was the size of 
the counterion. Sodium was larger than lithium and thus not able to fit between 
the axial 4,6-hydroxyls with the same efficiency as the lithium ion. This unique 
association was responsible for the axial hydroxyls being more acidic than the 
equatorial hydroxyl, which produced the regioselective benzyl protection. This 
series of reactions isolated the 2-position of compound 2-3 to enable further 
modification. 
Installation of the propyl azide was done by Williamson ether synthesis. 
First, 3-bromo-1-propanol is converted to the corresponding azide using simple 
SN2 conditions with sodium azide. It's important to note that the propanol 
derivative was used here instead of the ethanol derivative due to concerns of 
elimination in the etherification step. The azidopropanol was converted to the 
triflate using 2,6 lutidene and triflic anhydride. The triflate was used without 
purification to form the propyl azido ether 2-4 using proton sponge in DCM.213 
With the azide tag installed, the orthoformate was deprotected to 2-5 using 
pTsOH in methanol.212 Initially, oxidative debenzylation,214 specifically designed 




isolation of the pentaol product proved difficult. This particular deprotection 
scheme was used because the classical way to deprotect benzyl groups via Pd/C 
mediated hydrogenation is not tolerated by azide, which would be reduced to the 
corresponding amine derivative. 
In order to circumvent the purification problems presented, the 1,3, and 5 
hydroxyls were acylated using acetic anhydride and pyridine to produce 2-6. 
Following reprotection the aforementioned debenzylation was employed to 
produce the triacyldiol 2-7. This derivative is much easier to purify and isolate 
successfully than the previous method used. After the debenzylation step, the 
intermediate can either be acylated again to produce the peracetate 2-2 or 
deprotected using sodium methoxide in methanol100 to produce the pentaol 2-1. 
The peracetate derivative 2-2 is useful due to some studies showing that these 
acetylated compounds pass the cell membrane easier through passive transport. 
Upon entering the cell, they can be cleaved by intercellular esterases103,215 to 
reveal the bioactive form. These two compounds are the lead compounds that 
were used for the biological studies that will be discussed later. 
Compound 2-1 has been synthesized successfully 7 times in total. This is 
due to the large amounts typically needed to complete biological studies. Each 
round of total synthesis typically yields between 10 and 30 mg with the highest 
quanitity being 53 mg. Most cellular labelling studies take ~20 mgs to complete in 
triplicate. Over the course of growth curves, fluorescence studies, and TLC/MS 




is the 3-azido-1-propanol used to make the azidopropyl ether linkage is 
photosensitive in the alcohol form. One round of synthesis produced the propyl 
amine even though no reducing conditions are employed during this synthesis. 
2.4 Synthesis of 2-Azidomethyl myo-Inositol 
The lead alkyl azido compound 2-1 is an excellent candidate for initial 
studies, but it does have some limitations. Due to the capping of the 2-hydroxyl, 
all inositol metabolites requiring biological modification at that position would be 
blocked, thus preventing selective detection of those metabolites, for example, 
IP6. Another problem that arises in biological studies is that the 2-hydroxyl group 
is essential in the mannosylinositol phosphorylceramide (MIPC) pathway of 
yeast. Blocking this essential sphingolipid pathway results in cell mortality.216-217 
The development of the 2-azidomethyl inositol derivatives 2-7 and 2-8 remedies 
both problems by retaining the original hydroxyl in its original stereochemistry as 
well as installing the azidomethyl group in the position most tolerant of 
modification (Scheme 2-2).  
Synthesis of this derivative starts from the key dibenzylate intermediate 2-
3 in the azido propyl ether synthesis (Scheme 2-1). Swern oxidation of the 2-
hydroxyl results in the ketone 2-8, which is subjected to Wittig conditions using 
methyltriphenylphosphonium bromide to install the needed carbon as an alkene 
in 2-9. From there 2-9 is converted to n-epoxides 2-10 and 2-11 using mCPBA. 




rigidity and sterics presented by the oxa-adamantane cage and the benzyl 
groups are hypothesized to influence formation of the preferred stereoisomer.  
 
 
Scheme 2-2. 2-Azidomethyl myo-inositol derivatives 2-17 and 2-18. 
 
 Since the epoxidation conditions are not asymmetric, the steric crowding 
of the benzyl groups should hinder approach of mCPBA on the bottom face of 
the alkene. This should make the desired formation occur on the top face, which 
reinstalls the oxygen equatorially versus axially. 1H NMR data shows that one 
stereoisomer forms in a ~4:1 ratio based on the peak size of the known 
orthoformate proton (Figure 2-2). The stereoisomers were difficult to separate 
efficiently so they were carried together to the next step.  
After epoxidation the orthoformate group was deprotected using pTsOH in 




azide was made due to the difficulty of epoxide opening with a variety of known 
conditions. Orthoformate deprotection made separation of the two stereoisomers 
substantially easier as the triol. Flash chromatography was used to separate the 
two diastereomers 2-12 and 2-13 cleanly, but they have not been fully 
characterized at this point. Once they are fully characterized, the desired epoxide 
can then be opened using sodium azide to complete installation of the 
azidomethyl group. From there the synthesis can be completed using the same 
deprotection steps as the azido ether synthesis.  
 
 
Figure 2-2. 1H NMR of n-epoxide diastereomers 2-10 and 2-11. 
 
Before these synthesis schemes were devised, strategy one with direct 
hydroxyl replacement was explored. Initially, double inversion at C2 was explored 
using thionyl chloride to produce the axial chlorine in 2-19 (Scheme 2-3). 




The second route to C2 replacement was through a pressure driven reaction. 
Myo-inositol was added to a sealed tube with acetic anhydride and acetyl 
bromide to produce the bromopentacetate 2-26. This reaction also showed very 
inconsistent yields even though the procedure was followed verbatim several 
times. Yields were also low and the reaction conditions are extreme for the 
system.218 Recently Sureshan and co-workers devised a route to quickly and 
robustly capture 2-25 by converting the hydroxyl on the desired position to triflate 
using a one pot synthesis scheme.219 Ultimately, the failures associated with the 
initial approach inspired the designs used above.  
 
 
Scheme 2-3. Initial approaches to C2 hydroxyl replacement with azide. 
 
2.5 Experimentals 
All non-aqueous reactions were performed in flame dried glassware under 




reactions were as is unless stated otherwise. Dichloromethane (DCM), N,N-
dimethylformamide (DMF), and  tetrahydrofuran (THF) were obtained from an in–
house dry solvent system and stored over activated 4 Å molecular sieves under 
nitrogen atmosphere. All commercially available compounds were used as 
received without further purification. Reactions were monitored by thin–layer 
chromatography (TLC) carried out on 0.25 mm Sorbtech silica gel plates (60F-
254) under 254 nm UV lamp and stained by potassium permanganate solution. 
Flash chromatography was performed on silica gel 60 (0.040–0.063 mm). 1H, 
13C, and 2D NMR spectra were recorded on liquid state Varian VNMRS (500 
MHz). Chemical shifts are reported in δ (ppm) and calibrated using residual 
undeuterated solvents as an internal reference. The following abbreviations were 
used to explain the multiplicities: s=singlet, d=doublet, t=triplet, q=quartet, 
dd=doublet of doublet, dt=doublet of triplet, td=triplet of doublet, m=multiplet, 
br=broad. 1H NMR coupling constants (J) are reported in Hertz (Hz), Mass 
spectra were obtained on JEOL JMS-T 100 LC DART-TOF mass spectrometer.  
 
 
4,6-di-O-benzyl-1,3,5-methylidyne-myo-inositol (2-3): myo-Inositol (10 g, 54 
mmol), triethylorthoformate (16 mL, 96 mmol), and para-toluene sulfonic acid 
(2.11 g, 12 mmol) were dissolved in 100 mL of DMF in a 250 mL round-bottomed 




cool to rt and dry triethylamine (1.2 mL, 8.6 mmol) was added. The reaction 
mixture was concentrated under reduced pressure to afford a gummy solid, 
which was then dissolved in 250 mL of DMF in a 500 mL round-bottomed flask. 
Lithium hydride (4.11 g, 517 mmol) was added to the reaction mixture 
portionwise and stirred for an hour at rt. After an hour, the temperature was set to 
65 oC, and to the thick slurry was added benzyl bromide (16.5 mL, 139 mmol). 
The solution was stirred for 12 h. Ice was then added to the solution, which was 
then stirred for an additional 30 min. The reaction mixture was separated using 
DCM (3 x 100 mL), and the organic layers were collected and dried over MgSO4. 
The solvent was removed under reduced pressure, and the resulting gummy 
solid was run through a short plug of silica using 30% EtOAc/hexanes. The 
solvents were removed under reduced pressure, and the resulting yellow oil was 
dissolved in a mixture of methanol (10 mL) and water (2 mL) and allowed to 
crystallize overnight. The resulting crystals were washed with methanol then 
recrystallized in 15% EtOAc/hexanes to afford 2-3 (6.58 g, 32%) as colorless 
crystals. 1H spectra matched known literature.211 1H NMR (CDCl3, 500 MHz) δ 
4.20-4.22 (m, 1H), 4.23-4.25 (m, 2H), 4.38 (t, 2H, J = 3.7 hz), 4.45-4.48 (m, 1H), 
4.63 (dd, 4H, J = 39.5, 11.5), 5.47 (s, 1H), 7.28 (m, 10H). 
 
2-O-(3-azidopropyl)-4,6-di-O-benzyl-1,3,5-methylidyne-myo-inositol (2-4): To 




3-azido-1-propanol (0.650 g, 6.42 mmol), 2,6-lutidene (0.488 mL, 4.21 mmol)  
and triflic anhydride (0.712 mL, 4.21 mmol). The reaction was stirred at this 
temperature for one h. The reaction was then quenched with H2O (10 mL) and 
extracted (3 x 5 mL) with DCM. The organic layer was collected and dried over 
Na2SO4. The solvent was removed under reduced pressure, and the crude triflate 
was capped. Compound 2-3 (0.500 g, 1.35 mmol) and proton sponge (0.694 g, 
3.24 mmol) were added to a glass sealed tube. DCM (4 mL) was added to the 
tube along with a small stirbar and the crude azido-triflate. The tube was sealed 
tightly, and the reaction mixture was then stirred and heated at 85 oC for 12 h. 
The reaction mixture was allowed to cool to rt and then partitioned between H2O 
(15 mL) and DCM (3 x 15 mL). The organic layer was collected and dried over 
Na2SO4. The solvents was removed under reduced pressure and the crude oil 
was subjected to flash chromatography using 10% EtOAc/hexanes as eluent to 
afford 2-4 as a colorless oil (0.329 g, 58%) . 1H NMR (CDCl3, 500 MHz) δ 1.90 
(m, 2H), 3.44 (t, 2H, J = 6.6 Hz), 3.58 (t, 2H, J = 6.1  Hz), 3.90 (q, 1H, J = 1.69 
Hz), 4.29 (m, 2H), 4.37 (t, 2H, J = 3.2 Hz), 4.45 (m, 1H), 4.63 (dd, 4H, J = 69.2, 
11.7 Hz), 5.51 (s, 1H), 7.31 (m, 10H). 13C NMR (CDCl3, 125 MHz) δ 29.27, 
48.32, 65.86, 68.07, 68.36, 70.30, 71.95, 74.10, 103.20, 127.77, 127.99, 128.51, 






2-O-(3-azidopropyl)-4,6-di-O-benzyl-myo-inositol (2-5): Compound 2-4 (0.33 
g, 0.77 mmol), and para-toluene sulfonic acid (0.12 g, 0.72 mmol) were 
combined together in methanol (2 mL) in a 25 mL round-bottomed flask and 
stirred at rt for 24 h. All volatiles were removed under reduced pressure and the 
crude mixture was subjected to flash chromatography using 50% EtOAc/hexanes 
as eluant to afford 2-5 (0.23 g, 73%) as a clear oil. 1H NMR (CDCl3, 500 MHz) δ 
1.85 (m, 2H), 2.49 (t, 2H, J = 5.51 Hz), 3.38 (t, 2H, J = 6.6 Hz), 3.55 (m, 5H), 
3.81 (t, 1H, J = 2.6 Hz), 3.87 (t, 2H, J = 5.8 Hz), 4.86 (q, 4H, J = 11.4 Hz), 7.28-
7.40 (m, 10H). 13C NMR (CDCl3, 125 MHz) δ 29.32, 48.90, 70.92, 72.39, 75.05, 
80.21, 81.86, 127.98, 128.08, 128.63, 138.46. MS (DART-TOF, m/z): calcd for 
C21H25N3O6 (M + H)+ 416.1743. Found 416.2085. 
 
1,3,5-tri-O-acetyl-2-O-(3-azidopropyl)-4,6-di-O-benzyl-myo-inositol (2-5): 
Compound 2-5 (0.297 g, 0.671 mmol), DMAP (0.041 g, .336 mmol) and acetic 
anhydride (10 mL, 110 mmol) were dissolved in pyridine (30 mL) in a 100 mL 
round-bottomed flask and stirred at 65 oC for 12 h. The reaction was quenched 




organic layers were washed with brine, dried over sodium sulfate and the solvent 
evaporated under reduced pressure. The crude product was subjected to flash 
chromatography using 25% EtOAc/hexanes to afford compound 2-6 (0.291 g, 
74%) as an off-white solid. 1H NMR (CDCl3, 500 MHz) δ 1.80-1.85 (m, 2H), 1.87 
(s, 3H), 2.00 (s, 6H), 3.43 (t, 2H, J = 6.6 Hz), 3.64 (t, 2H, J = 5.7 Hz), 3.91 (t, 3H, 
J = 10.2 Hz), 4.59 (q, 4H, J = 11.7 Hz), 4.91 (dd, 2H, J = 10.2, 2.6 Hz), 5.16 (t, 
1H, J = 9.7 Hz), 7.21-7.34 (m, 10H). 13C NMR (CDCl3, 125 MHz) δ 20.78, 29.51, 
48.11, 70.26, 72.96, 73.52, 74.66, 127.56, 127.66, 128.36, 138.08, 169.60. 
 
1,3,5-tri-O-acetyl-2-O-(3-azidopropyl)-myo-inositol (2-7): To a solution of 2-6 
(0.100 g, 0.176 mmol) in EtOAc (2.5 mL) in a 50 mL round-bottomed flask was 
added a solution of sodium bromate (0.265 g, 1.73 mmol) in water (2 mL). A 
solution of sodium hydrosulfate (0.275 g, 1.58 mmol) in water (5 mL) was added 
dropwise over 10 minutes and the reaction was vigorously stirred for 24 h at rt. 
The reaction was then diluted with EtOAc (10 mL), quenched with 10% sodium 
thiosulfate (2 mL) and extracted with water. The combined organic layers were 
dried over MgSO4 and evaporated under reduced pressure. The crude product 
was then subjected to flash chromatography with a 50%-75% EtOAc/hexanes 
gradient to afford 2-7 (0.0435 g, 64%) as a clear oil. 1H NMR (CDCl3, 500 MHz) δ 




J = 5.7 Hz), 3.88 (s, 1H), 3.96 (t, 2H, J = 9.9 Hz), 4.90 (dd, 2H, J = 10.3, 2.5 Hz), 
4.95 (t, 1H, J = 9.6 Hz). 13C NMR (CDCl3, 125 MHz) δ 20.89, 21.01, 29.51, 48.02, 
69.86, 70.12, 73.44, 75.98, 170.71, 171.89. 
 
1,3,4,5,6-penta-O-acetyl-2-(3-azidopropyl)-myo-inositol (2-2): Compound 2-7 
(0.0435 g, 0.112 mmol), and acetic anhydride (5 mL, 50 mmol) were dissolved in 
pyridine in a 25 mL round-bottomed flask and stirred at 65 oC for 12 h. The 
reaction was quenched with saturated NaHCO3 (30 mL) and extracted with DCM 
(3 x 10 mL). The organic layer was washed with brine, dried over sodium sulfate 
and the solvent was evaporated under reduced pressure. The crude product was 
subjected to flash chromatography with 25% EtOAc/hexanes as eluent to afford 
2-2 quantitatively (0.0528 g) as a white solid. 1H NMR (CDCl3, 500 MHz) δ 1.87 
(m, 2H), 2.01 (s, 9H), 2.08 (s, 6H), 3.51 (t, 2H, J = 6.4 Hz), 3.71 (t, 2H, J = 5.7), 
3.98 (t, 1H, J = 2.5 Hz), 4.99 (dd, 2H, J = 10.5, 2.5 Hz), 5.13 (t, 1H, J = 9.7 Hz), 
5.54 (t, 2H, J = 10.1). 13C NMR (CDCl3, 125 MHz) δ 20.50, 20.58, 29.50, 47.85, 
69.76, 70.45, 70.92, 71.11, 76.56, 169.71, 169.73, 169.78. MS (DART-TOF, 





2-O-(3-azidopropyl)-myo-inositol (2-1): Compound 2-7 (0.0223 g, 0.0573 
mmol) was dissolved in dry methanol (4 mL) and sodium methoxide (0.0092 g, 
0.1719 mmol) was added to a 25 mL round-bottomed flask. The mixture was 
heated at 70 oC for 6 h after which the excess sodium methoxide was quenched 
with H2O. The contents were lyophilized and then reconstituted in 1 mL of H2O. 
Cation-exchange resin Amberlite IR-120 (pretreated with 2M HCl and H2O) was 
added and the mixture was vortexted for 5 min. The resin was removed by 
filtration with methanol and the filtrate lyophilized to afford 2-1 quantitatively 
(0.0134 g) as a white solid. 1H NMR (CDCl3, 500 MHz) δ 1.84 (m, 2H), 3.12 (t, 
1H, J = 9.2 Hz), 3.30 (m, 3H), 3.37 (dd, 2H, J = 9.9, 2.7 Hz) 3.44 (t, 2H, J = 
6.9Hz), 3.56 (t, 2H, J = 9.5 Hz), 3.69 (t, 1H, J = 2.7 Hz), 3.84 (t, 2H, J = 6.0 Hz). 
13C NMR (CDCl3, 125 MHz) δ 72.32, 73.22. MS (DART-TOF, m/z): calcd for 
C9H17N3O6 (M – N2)+ 236.1056. Found 236.1148 
 
4,6-di-O-benzyl-1,3,5-methylidyne-2-one-myo-inositol (2-8): DMSO (1.7 mL, 
24 mmol) in DCM (5 mL) was added dropwise to oxalyl chloride (1.0 mL,11 
mmol) in a 250 mL round-bottomed flask under N2 atmosphere dissolved in 20 
mL of DCM at -55 oC and the resulting solution was allowed to stir for 30 min. A 
solution of compound 2-3 (1.8 g, 4.9 mmol) in DCM (10 mL) was then added 
dropwise and the resulting solution was stirred at -55 oC for 1.5 h, after which the 




reaction mixture was allowed to stir and reach room temperature. The reaction 
mixture was then partitioned between H2O and DCM (20 mL each). The organic 
layer was collected, evaporated under reduced pressure, and subjected to flash 
chromatography with 15% EtOAc/hexanes as eluent to afford 2-8 (1.4 g, 78%) as 
a white solid. 1H spectra matched known literature.220 1H NMR (CDCl3, 500 MHz) 
δ 4.44 (m, 2H), 4.58 (m, 2H), 4.61 (d, 2H, J = 4.2 Hz), 4.64 (s, 1H), 5.30 (s, 4H), 
5.65 (s, 1H), 7.27 (m, 10H) 13C NMR (CDCl3, 125 MHz) δ 53.40, 68.82, 71.56, 
77.91, 102.64, 127.76, 128.45, 128.46, 136.84, 199.09. 
 
4,6-di-O-benzyl-2-deoxy-2-methylene-1,3,5-methylidyne-myo-inositol (2-9): 
Methyltriphenylphosphonium bromide (1.67 g, 4.7 mmol) that had been oven 
dried was suspended in THF (5 mL) under N2 at 0 oC. Potassium tert-butoxide 
(3.43 mL, 9.33 mmol) was added. The resulting yellow suspension was allowed 
to reach rt and then stirred at rt for 10 mins. A solution of compound 2-8 (0.80 g, 
2.2 mmol) in THF (8 mL) was added. The mixture was refluxed at 85 oC for 18 h. 
After reflux, the solvent was removed under reduced pressure and the residue 
was taken up in diethyl ether (10 mL), washed with brine (50 mL), and the 
solvent was evaporated under reduced pressure. The crude product was purified 
via flash chromatography with 10% EtOAc/hexanes as eluent to afford compound 




4.39 (m, 1H), 4.45 (s, 2H), 4.61 (q, 4H, J = 12.1), 5.24 (s, 2H), 5.57 (s, 1H), 7.28 
(m, 10H) 
 
4,6-di-O-benzyl-1,3,5-methylidyne-2-oxiranyl-myo-inositol Compound 2-9 
(0.50g, 1.4 mmol) was dissolved in DCM (5 mL) and cooled to 0 oC, after which 
the reaction was allowed to stir. m-CPBA (0.35 g, 2.0 mmol) was next added and 
the reaction mixture was stirred for 10 min. It was then allowed to warm to rt and 
stir for an additional 48 h. After stirring the reaction mixture was diluted with 20 
mL of acetone. The reaction mixture was then extracted from water (30 mL) with 
DCM (2 x 30 mL). The organic layers were combined and washed with saturated 
NaHCO3 (10 mL) followed by brine (10 mL) and water (10 mL), and then dried 
over MgSO4. The organic layer was evaporated under reduced pressure and 
purified via flash chromatography with 5% EtOAc/hexanes as eluent to afford a 
mixture of diastereomers 2-11 and 2-10 (0.1613 g, 31%) as a colorless oil. 1H 
NMR (CDCl3, 500 MHz) δ 2.78 (s, 2H), 2.94 (s, 2H), 3.80 (q, 2H, J = 1.6 Hz), 
3.85 (q, 2H, J = 1.9 Hz), 4.33 (t, 2H, J = 3.7 Hz), 4.40 (t, 2H, J = 3.7 Hz), 4.56 (m, 
4H), 4.65 (s, 1H), 4.66 (s, 1H), 4.68 (s, 1H), 5.60 (s, 1H), 5.64 (s, 1H), 7.27 (m, 
10H). 13C NMR (CDCl3, 125 MHz) δ 50.41, 53.39, 54.08, 68.38, 71.18, 71.66, 





CHAPTER THREE : 
BIOENGINEERING OF AZIDO-INOSITOL INCORPORATED LIPIDS 
AND BIOORTHOGONAL VALIDATION 
3.1 Introduction 
Bioengineering is a robust method to probe important cellular processes 
spatially and temporally. These methods have been used to better understand 
disease states, validate pathways and signaling cascades, and develop novel 
therapeutics. As one of the simplest eukaryotic organisms that still shows a great 
amount of gene homology with mammals, yeast cells are commonly used as 
models for understanding the intracellular events of mammalian cells. It is 
estimated that 31% of the yeast genes encoding for proteins share some kind of 
robust homology with mammals. They are also cheap and easy to maintain and 
manipulate.221 S. cerevisiae and C. albicans cell cultures were grown with the 
compound 2-1 in varying quantities and for different lengths of time in order to 
probe inositol metabolite incorporation. Incubated cells were subjected to the 
appropriate bioorthogonal click reaction to probe incorporation via fluorescence 
imaging, MS analysis, and TLC separation (Figure 3-1). Fluorescence data 
indicates successful infiltration of 2-1 into yeast cells by SPAAC conjugation with 
DBCO Cy3.  Fluorescence results also indicate 2-1 can be transported without 
ITR1 activity via fluorescence in an ITR1 transporter mutant of C. albicans. TLC 
indicates incorporation into native myo-inositol lipids with increased labelling from 






Figure 3-1. Biosynthetic incorporation and detection of tagged inositol 




3.2 Verification of Incorporation of Azido-Inositol Probes into S. 
cerevisiae 
3.2.1 Assessing Cytotoxicity of Azido-Inositol Probes  
One obstacle that is prevalent in metabolic labeling studies is cytotoxicity. 
Since unnatural derivatives are being used for these studies, it’s possible that 
they can exhibit cytotoxicity by inhibiting essential pathways or the enzymes that 
they act as substrates for. In order to assess cytotoxicity, growth curves were 
generated to observe growth kinetics under a variety of conditions. Cells were 
maintained in a complete synthetic media containing 2 % glucose, no inositol, 
and known amounts of nutrients as described by Jesch and co-workers.180 This 
media was used to avoid the inherent randomization of nutrient concentration in 
standard YPD media and induce expression of the INO1 gene in WT (wild type) 
cells. This was done to encourage maximum possible uptake of compound 2-1. 
S.cerevisiae was tested for uptake of our inositol compounds by conducting 
growth experiments in the above synthetic media. 
Initially 2-1 was used in growth studies to assess cytotoxicity (Figure 3-2). 
The target concentration was 10 μM due to earlier reports of it being the lowest 
concentration needed to induce optimal log phase growth after inositol 
starvation.45-46,51,55,169,180 Control WT cell cultures containing no natural myo-
inositol or compound 2-1 showed comparable growth rate kinetics to WT cells 




















S. cerevisiae BY4742 WT and ino1Δ with 2-1
ino1Δ- (-) ino (-) 2-1
ino1Δ- (0 uM) ino (10 uM)2-1
ino1Δ- (4 uM) ino (6 uM) 2-1
ino1Δ- (6 uM) ino (4 uM) 2-1
ino1Δ- (10 uM) ino (0 uM) 2-1
WT (-) ino (-) 2-1




ending OD value. This was encouraging to see as there was no cytotoxicity 
observed. The ino1Δ mutant was defective in the expression of the INO1 gene 
that converts glucose to inositol. Inositol deficient media should result in 
nonviable cells and lack of cell growth which was observed with the control 
lacking myo-inositol and compound 2-1. It was also exhibited with cells incubated 
with only 10 μM of 2-1. One possible explanation for this is that the produced 
inositol metabolites are capped at the C2 hydroxyl, thus preventing production of 
MIPC, which is an essential yeast sphingolipid.216-217,222-223 Other experiments 
would have to be done to confirm this hypothesis. Addition of inositol back to the 
growth medium at 4, 6, or 10 μM restored log phase growth in the mutant cells. 
 The peracylated derivative 2-2 was also used in growth curve studies 
(Figure 3-3). As previously mentioned, the peracetylated compound should be a 
comparable labeling candidate to 2-1 due to the action of intercellular esterases 
that can cleave the acetate groups to reveal the target compound. Increased 
lipophilicity from the acetate groups also allows 2-2 to passively enter cells more 
efficiently. Growth curve data with 2-2 was comparable to data with 2-1 except in 
the case of the ino1Δ mutant. The 4 and 6 μM concentrations of 2-2 showed 
growth kinetics half as robust as WT cells or cells not incubated with. This 
outcome was initially concerning as the structure of 2-2 doesn’t initially present a 
cause for concern for cytotoxicity. However, it was hypothesized that the DMSO 
used to solubilize 2-2 could be the cause for the growth attenuation.  




















S. cerevisiae BY4742 WT and ino1Δ with 2-2 
ino1Δ- (-) ino (-) 2-2
ino1Δ (-) Ino (10 uM) 2-2
ino1Δ (4 uM) Ino (6 uM) 2-2
ino1Δ (6 uM) Ino (4 uM) 2-2
ino1Δ (10 uM) Ino (-) 2-2
WT (-) ino (-) 2-2




In addition, we wanted to test the upper limits of compound concentration in the 
growth media (Figure 3-4). The selected concentration was 2 mM for both 2-1 (in 
H2O) and 2-2. Data indicates that the added DMSO in solution does affect log 
phase growth in a comparable way to 2-2 spiked samples, which suggests that 
DMSO is the cause of the observed stunted growth. Unfortunately, since 2-2 is 
poorly soluble in other viable solvents, it is still inconclusive to say 2-2 is not the 
cause of decreased cell viability. 2 mM 2-1 shows growth comparable to the 
negative control sample, while the positive control out grew all other samples 
present. With these results suggesting that 2-1 and 2-2 are both tolerated in 
S.cerevisiae even at elevated concentrations, metabolic incorporation and 
verification is the next step. 
3.2.2 Metabolic Incorporation and Verification via Fluorescence, TLC and 
MS 
The simple brewer’s yeast S. cerevisiae is an ideal candidate for biological 
engineering studies due to some of the characteristics mentioned in the 
introduction. Initial studies with S. cerevisiae and the azido tagged inositol sought 
to verify incorporation of the compound via fluorescence labelling. Additional 
inositol was not added since yeast cells are inositol prototrophs in the presence 
of glucose.20,47-48 The cells were grown in the presence of the tagged compound 
then subjected to SPAAC using DBCO-Cy3 (Figure 3-1, 3-4), a cyanine dye that 






























to a good history of cyanine dyes being able to successfully breach the yeast cell 
wall and enter the cell interior.224-225 Also, wash procedures using potassium 
cyanide facilitated rapid and efficient removal of excess, unbound dye which 
lowered the background fluorescence greatly. Another advantage of using 
cyclooctyne dyes specifically is reaction simplicity. The SPAAC does not require 
the copper catalysis step so less starting material is needed to carry out the 
conversion. This is also advantageous when performing in vivo studies as copper 
is cytotoxic. 
 Fluorescence labeling of treated cells confirmed bioengineering of the 
tagged inositol derivative into native cell inositol metabolites. Cells were started 
at a 0.2 OD for studies with no supplemented inositol to encourage uptake of 2-1 
or 2-2. After 6 hours, they were spiked with a solution of compound 2-1 or 2-2 
and allowed to grow for an additional 4 hours to facilitate log phase incorporation 
into inositol metabolites. Cells not treated with the tagged inositol displayed no 
measurable fluorescence signal above background. Treated cells displayed very 
intense fluorescence around the cell membrane, which would correspond to 
labelling of PIPns or GPIs (Figure 3-5). The fluorescence seemed to be localized 
in those areas with minimal fluorescence in the cytoplasmic areas indicating 
more abundance of labeled membrane bound lipids versus free InsPs. Dual 
channel imaging with DAPI as the co-stain yielded expected staining of cell 
nuclei to put the fluorescently labeled spots in context. All of these results were 











the same results under similar conditions. Unfortunately, 2-2 also did not produce 
any labeling.  
 In order to confirm this result and identify the labeled products, MS and 
TLC were employed. Unfortunately, neither investigative method proved 
particularly fruitful with these cells. During these studies, cells were grown under 
a variety of growth conditions to try to maximize uptake of azidoinositols. First 
WT cells were grown in two different minimal media, one with glucose and one 
without glucose. It was thought that growing cells without glucose could render 
the INO1 gene useless, forcing maximal expression of inositol transporters on 
the surface of cells to transport the azido inositols across the cell wall and 
membrane. Unfortunately, this did not prove to be a viable strategy because the 
cells are placed under very harsh conditions as well as the ability of yeast to 
regenerate glucose endogenously via gluconeogenesis. Since the capped C2 
position prevents further synthesis of MIPC, growth results were similar to INO1 
cells that were only fed 2-1 or 2-2 (Figures 3-2 and 3-3). Cells were also grown in 
this glucose deficient media with supplemented inositol. This made cells reach 
log phase, but they did not reach a robust stationary phase OD. This is likely due 
to the inability of S. cerevisiae to utilize inositol as a carbon source. These 
experiments were repeated in the glucose containing media and inositol was 
preferred over the azido inositols for metabolite incorporation. 
 MS verification of labeled PIPns has been a very arduous task. There have 




lipid metabolites. Early experiments used varying concentrations of 2-1 from 100 
μM to 700 μM incubated with cells in glucose deficient media (Figure 3-6, 3-7). 
Promising MS signals were not seen as being conclusive because of very low 
intensity, lipid backbones that are not known to S. cerevisiae, or mass overlap 
with natural lipids. Subsequent experiments using higher concentrations of 2-1 in 
line with figure 3-4 were also tried without any avail.  
 
 
Figure 3-6. Negative-ion mode detection of tagged inositol phospholipids in 
S. cerevisiae incubated with 2-1. 
 
 TLC trials showed no distinct labeling even after click conjugation 
methods. This lipid labelling experiment was run under the same conditions as 
the above MS analysis with similar result. The problem was thought to be cell 
count, which meant that the cells must be grown with glucose in the media to 



























fluorescent activity (Figure 3-8). The samples grown for MS and TLC detection 
were initially 5 mL cell cultures and later switched to 10 mL. The lower initial 
volumes used were to minimize the use of compound for efficient labeling. 
However, previous studies of PIPns and InsPs in MS used large culture volumes 
to obtain sufficient detection of endogenous products.226-227 With these obstacles 
in mind, the study organism was switched to C. albicans due to its general robust 
growth in a variety of conditions.  
 
 
Figure 3-7. Positive-ion mode detection of tagged inositol phospholipids in 





























Figure 3-8. TLC labeling of S. cerevisiae. 
 
3.3 Verification of Incorporation of Azido-Inositol Probes into C. 
albicans 
3.3.1 PI Synthase Competition Assay and Cytotoxicity Testing 
 The switch to C. albicans was predicated on a competition assay done by 
Chelsi Cassilly of the Reynolds Lab in the University of Tennessee Microbiology 
Department. The assay used PI synthase derived from the membrane of C. 
albicans with tritiated inositol to determine PI synthesis via scintillation counting 
on TLC (Figure 3-9). The assay showed that when 10 mM of 2-1 substrate was 
present, tritiated PI production was minimally decreased. When 25 mM of 2-1 
was in the assay, tritiated PI production was decreased by >50%.  In comparison, 
peracetylated derivative did not show any kind of competition with tritiated inositol 




analog was successfully inhibiting conversion of natural myo-inositol to PI. This 































































Figure 3-9. PI synthase competition assay. 
 
 These results prompted growth curve studies to assess cytotoxicity and 
uptake. C. albicans appears to be very loose with its preferences for nutrient 
uptake as evidenced by its ability to uptake 8 different carbohydrates besides 
myo-inositol via ITR1 (Table 1). This will be advantageous to bioengineering 
later. C. albicans was grown with both natural myo-inositol 1-1 and compound 2-
1. Results indicate that C. albicans growth is enhanced overall by incubation with 
2-1. Incubation with 2-1 at a 2 mM concentration showed very robust OD values 
in comparison to 2 mM of natural myo-inositol (Figure 3-10). Also, incubation with 
1 mM and 0.5 mM 2-1 show enhanced growth as well when compared to their 
natural myo-inositol counterparts. This was an unexpected outcome, but there is 





































Since 2-1 is an unnatural myo-inositol substrate, it’s possible that it does 
not repress phospholipid synthesis through the UASINO element the same way 
that myo-inositol does. This would leave PI synthase constitutively expressed in 
the absence of environmental myo-inositol and formation of endogenous myo-
inositol via conversion from glucose. PI synthesis would be enhanced in the 
presence of a pool of 2-1 thus increasing rate of replication. The problem of C2 
hydroxyl capping in the MIPC pathway would be solved by cells converting 
glucose in the media to myo-inositol, which could satisfy inositol sphingolipid 
synthesis. This is further corroborated by the fact that even in the presence of a 
similar concentration of natural myo-inositol; cells only reach approximately half 
of the OD of the cells incubated with synthetic derivative 2-1. Cells were not 
tested with 2-2 after results suggested that the DMSO needed to solubilize it 
would hinder growth of cells as well as no positive indication of incorporation via 
fluorescence in the previous S. cerevisiae data. 
3.3.2 Metabolic Incorporation and Verification via Fluorescence, TLC and 
MS 
Fluorescence labeling yielded the same positive results as S. cerevisiae. 
A range of substrate concentrations from 0.75 mM to 2 mM of the azido tagged 
compound showed fluorescence in the wild type yeast cells (Figure 3-11). The 
dose dependence did not seem to alter the fluorescence intensity or location in 
an appreciable fashion. A concurrent experiment was also run using an ITR1 









These cells were incubated with 1 mM of compound 2-1 and also showed 
fluorescent activity confirming in part that some if not all of the tagged substrate 
is entering the cell via a different mechanism (Figure 3-12). The mechanism 
could be passive transport, which would just be diffusion down a concentration 
gradient into the cell. It could also be up–taken via another transporter such as 
ITR2 or a different carbohydrate transporter. This is an important observation as 
it shows that 2-1 is not restricted to utilizing ITR1 to enter cells and thus may not 
be subject to the same regulatory mechanisms as natural myo-inositol. This is 
also reflected in previous studies in substrate specificity of the C. albicans ITR1 
protein.22 This would further corroborate previous growth curve observations. 
 The next step of confirmation of bioengineering is TLC labelling. Initially 
the cells were grown in the presence of 1 mM of 2-1, lysed and the lipids were 
extracted, and reacted under normal CuAAC conditions using 10 µM TAMRA-
alkyne dye, 250 µM of a pre-mixed aqueous CuSO4/THPTA solution, and 100 
mM of sodium ascorbate solution. The first iteration of the experiment did not 
produce any fluorescently labeled lipid products. After some tweaking of the click 
reaction, specifically switching the solvent system to 55% aqueous DMSO from 
100% DMSO, fluorescently labeled lipid products were strongly labeled (Figure 
3-13). The labeled products are present at Rfs observed for natural PIPns in 
comparable solvent systems.228 Some of the recovered lipid material in lane f 
was lost in transit to the plate, which is why it appears to have weaker labeling 










Figure 3-13. Fluorescent and bright-field TLC images of labeled inositol 
products in C. albicans at 1 mM of 3-4. 
 
Next, a dose-dependent TLC experiment was done to see what effect a 
range of concentrations would have on lipid labeling. Once again labeling was 
confirmed due to a dose dependent intensity increase in labeled products. Also 
worthy of note is the appearance of new labeled bands as the substrate 
concentration increases. There are also multiple bands that have very close Rfs. 
It is hypothesized that those are different PIPn isomers of the same 
phosphorylation class according to previous attempts at resolving these isomers 
(Figure 3-14).229 One way to check this hypothesis in the future is to treat these 
samples with phosphatase enzymes to see if the Rf values change. With strong 
evidence of inositol lipid labeling, the next step was to identify the labeled 









 MS identification of the labeled lipids was performed after they were 
recovered from the TLC plate. The bands with similar RFs were combined and 
subjected to LC/MS-MS. The analyzed bands returned identification of masses 
corresponding to a 34:1 PI species as well as the TAMRA conjugated azido 
inositol starting material (Figure 3-15). This result along with the above evidence 
proves the incorporation of the tagged inositol into native inositol metabolites. 
3.4 Conclusion 
This system presents some great advantages in studying myo-inositol 
metabolism. Since the cell is able to incorporate the tagged derivatives, we 
expect to be able to capture most of the products at any point in the myo-inositol 
cycle as a PIPn or an InsP. This is important for studying stress responses in the 
cell and how they affect the production of the myo-inositol metabolites. Future 
studies with compounds 2-17 and 2-18 will theoretically allow for more robust 
and specific labeling. This should especially be true in the S. cerevisiae ino1Δ 
mutant cells since all 6 hydroxyl groups will be conserved, which is similar to the 
natural myo-inositol these cells are auxotrophs for. 
Retaining the C2 hydroxyl in these probes should allow cells to be grown 
in glucose rich media without fear of the synthetic inositol derivatives being 
eschewed as the preferred substrate. This additionally means that all inositol 
metabolites produced in this system will bear an azide moiety that can be easily 
conjugated as described above. Also, since IPC synthase facilitates the transfer 









sphingolipids, this synthase has been established as essential for cellular 
function and has not been found in mammals. This has made it a very desirable 
antifungal target.216,222-223 2-17 and 2-18 could allow investigation of this pathway 
further for the possibility of new antifungals. 
Some of the disadvantages of this study include the inability to capture all 
metabolites due to etherification of the 2 hydroxyl of 2-1 as discussed previously. 
This inhibits the identification of IP6 as well as the mannosylated phosphoinositol 
sphingolipids. Another disadvantage comes from identification of specific 
isomers. As mentioned above, several different PIPn and InsP stereoisomers 
exist and the current methods for identification and quantification such as TLC 
and MS are not capable of identifying specific isomers.  Going forward, there is a 
need for experimental methods to identify the different isomers present. 
3.5 Experimentals 
 The S. cerevisiae wild type and ino1Δ strain BY 4742 and C. albicans wild 
type and itr1ΔΔ SC 5314 strains were maintained on yeast 
extract/peptone/dextrose (YPD) plates (1% yeast extract, 2% bactopeptone, 2% 
glucose, and 2% agar). All experiments were performed using chemically defined 
synthetic complete media containing (per liter): 20 g of glucose, 5 g of 
ammonium sulfate, 1 g of potassium phosphate, 0.5 of g magnesium sulfate,1 g 
of sodium chloride, 0.1 g of calcium chloride, 0.5 mg of boric acid, 0.04 mg of 
cupric sulfate, 0.1 mg of potassium iodide, 0.2 mg of ferric chloride, 0.4 mg of 




biotin, 400 μg calcium pantothenate, 2 μg of folic acid, 400 μg of niacin, 200 μg of 
p-aminobenzoic acid, 400 μg pyridoxine hydrochloride, 200 μg of riboflavin, 400 
μg of thiamine, 20 mg of adenine sulfate, 20 mg of arginine, 20 mg of histidine, 
60 mg of leucine, 230 mg of lysine, 20 mg of methionine, 300 mg of threonine, 20 
mg of tryptophan, and 40 mg of uracil. Fluorescence microscopy images were 
taken on a Leica SP8 Confocal Microscope. TLC images were taken with an 
iPhone 6 camera. Fluorescent TLC images were taken with a GE Typhoon Trio 
Fluorescence Chemiluminescent Imager and Scanner. 
 
Growth Curve Protocol: Yeast strains were added to 25 mL of synthetic 
minimal media (-) inositol and incubated at 30 oC with medium shaking for 24 
hours. After 24 hours, an OD measurement was taken and 5 mL of fresh 
synthetic minimal media was inoculated with cell preculture to an OD of 0.2. 
Samples were spiked with a defined concentration of 2-1 or 2-2 and incubated at 
30o C with medium shaking. Every two hours, a culture sample was taken and 
read for optical density. This was done for a minimum of 12 hours and then a 24 
hour reading was taken to assess lag phase characteristics. Cells used for 
further studies were centrifuged. The supernatant was discarded and the cells 
were frozen at -78o C overnight. 
 
Metabolic Labeling Growth Protocol: Yeast strain was added to 25 mL of 




for 24 hours. After 24 hours, an OD measurement (1 mL, 10x dilution of 
preculture) was taken in order to calculate the cell volume needed for the initial 
OD value and 5 mL of fresh synthetic minimal media was inoculated with cell 
preculture to an OD of 0.2. This inoculum was incubated at 30 oC with medium 
shaking for 6 hours. The study samples were spiked with a defined concentration 
of 2-1 (40 mM stock in milli-q water) or 2-2 (40 mM stock in DMSO) to reach 
desired incubation concentration and allowed to stir for another 4 hours. After 4 
hours the cells were centrifuged (4,000 RPM, 3 min). The supernatant was 
discarded and the cells were frozen at -78 oC overnight. 
Fluorescent Copper-Free Click Protocol: After cell thaw (if needed), cells were 
washed and centrifuged (4,000 RPM, 5 min) twice with milli-q water (5 or 10 mL 
depending on initial experimental volume). Cells were then resuspended in equal 
amount of milli-q water that was discarded as supernatant. Next, 500 μL of 
labeled cells were added to 2 mL eppendorf tube. Dye 3-4 was added to cell 
culture to reach a total concentration of 10 μM and the resulting solution shaken 
for 1.5 hours covered with aluminum foil. Cells were centrifuged (13,000 rpm, 5 
min) and the supernatant was discarded. An alternate wash and centrifuge was 
then performed with the following: 1 mL milli-q water, 1 mL saturated NaCl, 1 mL 
45 mM Potassium Cyanide, and 1 mL milli-q water 2x for 5 wash and centrifuge 
cycles total. After the last centrifugation, cells were resuspended in 200 μL of 
milli-q water. 2 μL of cell culture were next mounted onto a microscope slide 




cover slip was placed on top of the cell inoculum and allowed to dry for 24–48 
hours. Slips were sealed with acrylic nail polish then imaged on a Leica SP8 
confocal microscope. 
Lipid Extraction Protocol: The cell pellets were thawed and then extracted with 
5 mL of 95% ethanol–water–diethylether–pyridine–concd NH4OH 15: 
15:5:1:0.018 (by vol) for 15 min at 60 °C. The extract was removed after 
centrifugation (4000 RPM, 3 min) and the pellet extracted twice more in the same 
manner into 20 mL glass screw cap vials. The lipid solutions were then dried over 
a stream of nitrogen overnight. After drying, lipid pellets were either resuspended 
in 200 μL 9:1 MeOH/CHCl3 with 5 μL of piperidine solution (300 mM stock 
solution in water) added for MS analysis or subjected to TLC click protocols as 
follows. 
TLC Click Reaction Protocol: Lipid pellets were dissolved in 500 μL of DMSO 
in a glass screw cap vial. 3-1 (40 mM stock in milli-q water, 250 μM final conc) in 
DMSO followed by CuSO4/THPTA complex (dissolve 50 mg of copper(II) sulfate 
pentahydrate in 10 mL of distilled water. Dissolve 95 mg of THPTA ligand in 11 
mL of DMSO. A mix of two solutions, (10 mM stock, and 500 μM final conc) was 
added. Sodium ascorbate (1 M stock in milli-q water, 25 mM final conc) was then 
added followed by water to a total volume of 1 mL, and the vials were sealed and 
heated at 70 oC for 18 h. After the reaction was stopped, 5 mL of water and 3 mL 




collected and then the aqueous layer was extracted again with 3 mL of 
chloroform and vortexed. The respective organic layers were combined and then 
washed twice with 4 mL of 45 mM KCN and once with 10 mL of water. The 
organic layers were collected and dried under a stream of nitrogen overnight. 
The clicked lipid extract was then dissolved in 100 μL of chloroform and applied 
to the TLC plate. The elution gradient used was 
chloroform/acetone/methanol/acetic acid/water (46/17/15/14/8, v/v). 
Fluorescence images were taken on a GE Typhoon Trio imager set to scan for 
fluorescence. Laser gain used was variable from 250 PMT to 500 PMT 
depending on background intensity. Bright field images were taken with a stock 




CHAPTER FOUR : 
INHIBITION AND INDENTIFICATION OF THE 
PHOSPHATIDYLSERINE SYNTHASE ACTIVE SITE 
4.1 Design of Serine and Cysteine Analogs for PS Synthase 
Inhibition and Mapping 
 In yeast, phosphatidylserine is synthesized via the CDP-DAG pathway like 
many other phospholipids by utilizing CDP-DAG with an appropriate head group. 
Though the process is well known, the mechanism and active–site residue 
composition is not. It is thought that the PS synthase mechanism works via 
general acid/base catalysis in the active site. By introducing an electrophilic 
trap/tag into an analog of a substrate, peripheral basic residues could act as a 
nucleophile displacing the electrophile, resulting in covalent/irreversible bonding 
to the active site.230 This will inhibit the activity of the enzyme, which can be 
detected using enzymatic conversion assays. With the active site tagged, the 
enzyme can be digested to obtain a profile of the amino acid (AA) residues in the 
active site. The native substrate serine is the best candidate for this modification 
at either the R-group or the amino terminus in order to identify the location of the 
serine binding domain. Cysteine is also a good candidate since the only 
difference in structure is the substitution of sulfur for oxygen in the R-group. 
Another consideration is the addition of a secondary reporter tag to the trapping 




again an ideal candidate due to aforementioned qualities. Progress towards a 
series of PS synthase inhibitors are described ahead.  
 
4.2 General Synthetic Outline 
 Chelsi Cassily of the Reynolds lab has obtained data that suggests the 
optimal places to attach these electrophilic traps. PS synthase inhibition assays 
similar to the PI synthase assays run previously using 2-1 indicate that the area 
of most robust activity is  O/S-terminus of the side chain and the N-terminus of 
the amino group. Results indicate that propyl length electrophile traps on either 
terminus inhibit activity by greater than 50% at 5 mM concentrations. Serine 
reacts with CDP-DAG via the side chain hydroxyl, so it is logical to predict that 
end of the molecule will be exposed to the residues facilitating catalytic activity. 
This is also based on the proposed acid/base catalytic activity of serine 
proteases (Figure 4-1).231  
This catalytic mechanism has been proposed as the same mechanism 
used by the CDP-DAG pathway based phospholipid synthases. It is believed that 
in the active site of these synthases there are certain acidic and basic residues 
like histidine and aspartic acid that facilitate conversion of amides to create 
carboxylic acids using water. In the case of the phospholipid synthases, it would 
be headgroup transfer to CDP-DAG. Both acidic and basic residues tend to be 
amphiphiles in the active site of proteins. This is advantageous for trapping 





Figure 4-1. Mechanism of serine proteases and proposed irreversible 





Figure 4-2. Serine and cysteine modification with electrophilic tags or 
bifunctional tags to probe PS synthase location and active site 
composition. 
 
Both the side chains and the amine terminus either have native 
nucleophilic character or can be easily converted into suitable nucleophiles for 
use with alkyl halides (Figure 4-2). Alkyl halide substitution, specifically of 
dibromoalkyl materials, provides a facile way to produce the desired electrophilic 
tag with a variable linker length. A propyl linker was chosen for the initial 
synthetic scheme, but this linker length can easily be changed depending on 
results. Another aspect to consider is that the starting material has to be 
protected at the appropriate moieties to isolate either the free amine or the side 
chain thiol/hydroxyl and attach the appropriate trap linker. Use of the 
conventional linker with just the electrophilic trap will facilitate active site inhibition 
with the ability to detect the attached active site AA residue via MS. Use of the 




appropriate fluorescent alkyne dye when incubated with cells in vivo. Additionally, 
affinity chromatography can assist with the pull down of trap-conjugated PS 
synthase or isolation of conjugated AA residues after appropriate protein 
digestion protocols. 
4.3 Synthesis of S-Bromopropylcysteine Hydrochloride 
 
 
Scheme 4-1. Synthesis of S-bromopropylcysteine hydrochloride. 
 
Starting with 4-1, triethylamine was used to generate the needed thiolate 
to produce 4-2 according to conditions devised by Fiore and co-workers in their 
synthesis of S-glycosyl amino acids (Scheme 4-1).232 With the needed 
bromoalkyl linker attached, the last step is deprotection of the Boc group and the 
methyl ester. Deprotection of the Boc group first with phosphoric acid results in 
cyclization product 4-14 that was detected via NMR after workup and purification. 
A dual deprotection scheme utilizing 4.5 M hydrochloric acid233 was used instead 




4.4 Synthesis of O-Bromopropylserine Hydrochloride 
 
 
Scheme 4-2. Synthesis of O-bromopropylserine hydrochloride. 
 
This synthesis starts with N-Boc-L-serine methyl ester 4-4. Because of the 
poor S-H bond overlap, thiols are significantly more acidic than alcohols. 
Therefore, triethylamine is not a suitable base to create the needed alkoxide 
nucleophile. Surprisingly, metal hydrides like sodium hydride also only returned 
starting material upon attempted conversion. Synthesis of the azido propyl linker 
used in 2-4 also presented a difficult to convert hydroxyl, so the same 
conditions213 were applied here to accomplish etherification (Scheme 4-2). While 
low yielding, the conversion to 4-5 was successful using 3-bromo-1-propanol as 
the bromoalkane substrate. The same dual deprotection scheme for the Boc 
group and methyl ester was used here to once again capture the bromopropyl 
linked serine hydrochloride salt 4-6. 
4.5 Synthesis of the Dibromoazide Linker and Azidomethyl S-
Bromopropylcysteine Hydrochloride 
 A bifunctional linker has a significant appeal in these studies due to the 




can by fluorescently detected111,130-131 or purified via biotinylation and affinity 
chromatography.105,148,234 Both of these methods would be attractive for probing 
protein localization and active site residue composition of PS synthase. Previous 
methods tried to selectively convert the alcohol group of a previously synthesized 
dibromobutanol235 to the corresponding azide. Most of these conversions either 
result in irreproducibility or extreme difficulty in separating side products from the 
desired product so a new route was devised.  
 
 
Scheme 4-3. Synthesis of azidomethyl 1,3-dibromopropane. 
 
The initial starting material 4-7 is an acetonide protected triol with one free 
hydroxyl group (Scheme 4-3). This hydroxyl group will be tosylated followed by 
azidation to 4-8 and deprotection of the acetonide group to reveal the azido diol 
4-9.236 The diol will be ditosylated to 4-10 then displaced by sodium bromide to 
complete the synthesis of the bifunctional dibromoazide 4-11. This 
dibromoalkane derivative can then be subjected to the same conditions 
previously used232-233 in the synthesis of 4-3 above to capture the bifunctional 





Scheme 4-4. Synthesis of azidomethyl S-bromopropylcysteine 
hydrochloride. 
 




































































Figure 4-3. PS synthase assay results using both inhibitor candidates. 
 
The lead compounds for inhibition studies are the S- and O-bromopropyl 
linked AA salts 4-3 and 4-6. An assay similar to the previously used PI synthase 
competition assay is used to assess PS synthase inhibition. This assay is also 
run by Chelsi Cassilly of the Reynolds microbiology group. Data suggests that 
the O-bromopropyl-L-serine hydrochloride is a poor candidate for serine active 
site inhibition ironically (Figure 4-3). Turnover of tritiated PS was generally 




bromopropyl-L-cysteine hydrochloride showed great inhibition relative to 
substrate concentration. The initial batch of compound inhibited production of 
tritiated PS by 50% at 5 mM. A subsequent batch of this compound showed 
comparable inhibition dynamics though slightly reduced from the first batch. This 
is an encouraging result as the next step is pulldown of the inhibited protein for 
digestion and subsequent MS detection.  
The goal of these studies is to use inhibitor treated PS synthase to pull 
down this enzyme from whole cell extract and digest using an appropriate 
enzyme, commonly trypsin. After digestion, the sample will be subjected to MS 
analysis. The hope is to detect fragments that have extra mass comparable to 
the trapped active site substrate. This is determined by simultaneous digestion of 
untreated PS synthase as a control. Found fragments will then be compared to 
fragments of inhibitor treated PS to find the appropriate mass difference in 
fragments of the treated PS synthase. The fragments are then further analyzed 
for specific amino acid residue composition to map the active site. If there are 
multiple residues that exhibit this extra mass difference, this would further 
elucidate what AA residues are utilized in head group transfer of serine to CDP-
DAG. These studies are currently being performed by Chelsi Cassilly in the 
Reynolds group. For probes of type 4-3, the target protein can be isolated using 
an affinity chromatography tag. Following the completion of clickable analogs 
such as 4-13, click chemistry can be used to purify covalently labeled amino acid 





 Inhibition and mapping of PS synthase represents a very exciting avenue 
for studying the mechanism of phospholipid synthesis, especially phospholipids 
synthesized via the CDP-DAG pathway. Initial data obtained using these 
derivatives is promising toward these goals. This type of mechanistic probe into 
active site substrate composition is very novel and possibly adaptable to other 
phospholipid synthases. Early inhibition data supports the hypothesis in part of 
covalently binding to key residues. This will allow verification that there are AA 
residues that can act as nucleophiles in the active site. This will lend some 
credence to the proposed mechanism, but it could also mean that there are 
simply nucleophilic residues present in the active site (Figure 4-1). Since the PS 
synthase active site has never been identified, this project represents a 
potentially groundbreaking discovery in phospholipid targeting. Future studies 
with the bifunctional linker will be able to build upon the precedent established 
thus far to further elucidate early findings. Also, studies with derivatives not 
bearing the electrophilic trap at the end of the alkyl chain can be used to confirm 







methyl S-(3-bromopropyl)-N-(tert-butoxycarbonyl)cysteinate (4-2): To a 
solution of 4-1 (0.512 g, 2.20 mmol) in DCM (20 mL) in a 100 mL round-bottomed 
flask were added triethylamine (1.50 mL, 10.5 mmol) and 1,3-dibromopropane 
(1.32 g, 6.52 mmol). The solution was stirred at rt for 18 h, diluted with DCM, and 
then washed with H2O (3 x 10 mL). The organic layer was collected and dried 
with MgSO4. Volatiles were removed under reduced pressure and the residue 
was subjected to flash chromatography with 12.5% EtOAc/hexanes as eluent to 
yield 4-2 (0.2904 g, 38%) as a pale yellow oil. 1H NMR (CDCl3, 500 MHz) δ 1.44 
(s, 9H), 2.08 (m, 2H), 2.68 (t, 2H, J = 7.0 Hz), 2.96 (m, 2H), 3.47 (t, 2H, J = 6.2 
Hz), 3.76 (s, 3H), 4.53 (bs, 1H), 5.35 (bs, 1H). 13C NMR (CDCl3, 125 MHz) δ 
28.28, 30.87, 31.77, 32.08, 34.54, 52.58, 53.31, 80.17, 155.06, 171.39. MS 
(DART-TOF, m/z): calcd for C12H22BrNO4S (M + H)+ 356.0453. Found 356.0482. 
 
General procedure A for obtaining O/S-bromoalkyl serine/cysteine 
hydrochloride salts: The protected O/S-bromoalkyl serine/cysteine was added 
to 4.5 M HCl and then heated with stirring for 16 h. After cooling, the aqueous 
phase was diluted with H2O (10 mL) and washed with diethyl ether (10 mL). The 
aqueous phase was then evaporated under reduced pressure delivering a solid 
which was triturated with diethyl ether. After decanting and drying, the salt was 





2-((3-bromopropyl)thio)-1-carboxyethan-1-aminium chloride (4-3): General 
procedure A was followed with 4-2 (0.076 g, 0.219 mmol) and 4.5 M HCl (2 mL) 
to afford 4-3 (0.017 g, 27%) as a light brownish orange solid. 1H NMR (MeOD, 
500 MHz) δ 2.06 (m, 2H), 2.78 (td, 2H, J = 7.3, 1.4 Hz), 3.07 (dd, 1H, J = 14.7, 
7.5 Hz), 3.18 (dd, 1H, J = 14.8, 4.3 Hz), 3.30 (m, 2H), 3.69 (t, 2H, J = 6.3 Hz), 
4.22 (broad s, 1H). 13C NMR (MeOD, 125 MHz) δ 28.52, 29.72, 31.11, 31.13, 
31.19, 32.56, 43.56, 52.35, 170.82 
 
methyl O-(3-bromopropyl)-N-(tert-butoxycarbonyl)serinate (4-5): To a DCM 
solution (10 mL) in a 50 mL round-bottomed flask at -78 oC were added 3-bromo-
1-propanol (0.410 g, 2.95 mmol), 2,6 lutidene (0.412 mL, 3.56 mmol) and triflic 
anhydride (0.598 mL, 3.56 mmol) and the resulting solution was stirred for 1 h. 
The reaction was then quenched with water (5 mL). The reaction mixture was 
extracted with 15 mL of DCM. The organic layer was collected and dried over 
Na2SO4. Solvents were removed under reduced and the crude triflate was 
capped. Compound 4-4 (0.340 g, 1.55 mmol) and proton sponge (0.586 g, 2.74 
mmol) were added to a glass sealed tube. 4 mL of DCM was added to the tube 
along with a small stirbar and the crude bromo triflate. The tube was sealed 
tightly and then stirred and heated at 60 oC for 12 h. The reaction mixture was 
allowed to cool to rt and then partitioned between H2O (15 mL) and DCM (3 x 15 




removed under reduced pressure and the crude oil was subjected to flash 
chromatography with 10% EtOAc/ hexanes as eluent to afford 4-5 (0.0623 g, 
12%) as a colorless oil. 1H NMR (CDCl3, 500 MHz) δ 1.44 (s, 9H), 2.04 (m, 2H), 
2.79 (broad s, 1H), 3.43 (t, 2H, J = 6.5 Hz), 3.54 (m, 2H), 3.66 (dd, 1H, 9.4, 3.3 
Hz), 3.75 (s, 3H), 3.83 (dd, 1H, 9.4, 3.3 Hz), 4.41 (broad s, 1H), 5.31 (broad s, 
1H). 13C NMR (CDCl3, 125 MHz) δ 28.29, 30.20, 32.38, 52.46, 53.96, 68.66, 
70.91, 80.00, 155.41, 171.07. MS (DART-TOF, m/z): calcd for C12H22BrNO5 (M + 
H)+ 340.07. Found 340.03. 
 
 
2-(3-bromopropoxy)-1-carboxyethan-1-aminium chloride (4-6): General 
procedure B was followed with 4-5 (0.0623 g, 0.184 mmol) and 4.5 M HCl (2 mL) 
to afford 4-6 (0.0412 g, 86%) as a light brownish orange solid. 1H NMR (MeOD, 
500 MHz) δ 2.03 (m, 2H), 3.30 (s, 1H), 3.66 (m, 4H), 3.87 (dd, 1H, J = 10.5, 3.2 
Hz), 3.94 (dd, 1H, J = ,10.5, 3.2), 4.21 (t, 1H, J = 3.31). 13C NMR (MeOD, 125 





CHAPTER FIVE : 
SYNTHESIS OF SI-BASED NEAR-IR DYE FOR CLICK 
VISUALIZATION AND PHOTOCAGED GLUTAMIC ACID FOR 
PHLIP STUDIES 
5.1 Near-IR Fluorogenic Rhodamine Dye 
 Fluorogenic dyes are of significant interest in the chemical biology 
community. Fluorogenic dyes are typically compounds that do not exhibit any 
fluorescence until chemically altered by some kind of reaction. These dyes are 
very useful because they exhibit minimal fluorescence prior to reaction, which 
means background fluorescence is attenuated; further enhancing the contrast 
between labeled products of interest. These conversions can be initiated by 
enzymes237-239 or by lab reactions such as click chemistry. 104,111,130 The dyes 
synthesized for click reactions often have a fluorescence excitation profile 
between 320-350 nm, which is very close to the natural fluorescence profile of 
biomolecules like proteins.240-241 In order to circumvent this problem, groups 
focused on creating dyes that would have a near-IR fluorescence profile.242-244 
 The dye that was pursued was originally reported by the Bertozzi group by 
Shieh et al (Scheme 5-1).244 It was pursued due to problems encountered with 
fluorescence visualization of cells incubated with compound 2-1. Initial attempts 
of fluorescent dye conjugation to 2-1 incubated cells resulted in high background 














problem. This rhodamine derivative was originally synthesized for conjugation to 
the peptidoglycan layer of bacterial cells and later refined to label mammalian cell 
surfaces. The dye exhibits a 48-fold increase in fluorescence upon CuAAC or 
SPAAC conjugation. This allowed the authors to perform click procedures that 
did not require subsequent wash steps to expel unbound dye. The dye was 
synthesized using a silicon based xanthone ring characteristic of various 
rhodamines. Silicon in place of C10 of the xanthene chromophore produces a 
dramatic red shift in fluorescence profile.245 This particular dye was targeted for 
synthesis due to problems with labeling that were encountered after metabolic 




Scheme 5-2. Si-xanthone synthesis. 
 
 Synthesis of the Si-xanthone was very straightforward and was performed 
as described previously (Scheme 5-2).244-247 Yields for intermediates were 




straightforward. Unfortunately, the pendant coupling step was consistently 
unsuccessful. One possible reason is solvent dryness and air sensitivity. The 
pendant coupling was performed in a glove box in the original paper which our 
lab is not equipped with. There are several milligrams of xanthone and pendant 
compound left to pursue this synthesis if the appropriate glove box is obtained by 
the lab. 
5.2 Photocleavable Glutamic Acid for pHLIP Studies 
 The novel peptide called pH low insertion peptide (pHLIP) is designed to 
target cancer cells since the environment around cancer cells is more acidic than 
healthy cells. The peptide loosely associates with cell surfaces at pH 7.4, but 
inserts through the cell membrane as a stable transmembrane alpha helix upon 
contact with pH < 7.0 (Figure 5-1).248 Several therapeutics and studies249-255 have 
resulted since the creation of this peptide that was inspired by a previous 
membrane spanning peptide.256  
 Justin Westerfield, a graduate student in the lab of Francisco Barrera in 
the UTK Department of Biochemistry, Cellular and Molecular Biology is studying 
the kinetics associated with pHLIP peptide insertion into membranes. Towards 
this end, we are inserting a photocaged glutamic acid (Glu) derivative into the 
normal pHLIP peptide sequence to enable light activation properties that has 
been previously used to manipulate cell proliferation257 and DNA synthesis.258 
Upon light excitation, this photoswitch will reveal the acidic side chain of the glu 










pHLIP to trigger membrane insertion so that the kinetics can be studied 
accurately (Figure 5-1).  
 
 
Scheme 5-3. Synthesis of photocleavable Glu derivative for pHLIP 
engineering. 
 
5-16 has been reported previously, but it was synthesized through a 
different method. The nitroacetophenone precursor 5-13 was directly purchased 
instead of being synthesized in house. It was then reduced to the alcohol 5-14 
and coupled to the protected Fmoc glutamic acid directly at the side chain 
carboxylate to capture 5-15. The tert-butyl group was then deprotected using 
TFA to complete the synthesis of 5-13. The final step is low yielding due to 
competitive cleavage of the benzyl ester photocage. Previous synthesis schemes 
have not reported this competitive cleavage, only high yielding mono–cleavage of 
the tert-butyl ester. If future compound is needed, it would be wise to work to 







diyl))bis(oxy))bis(ethan-1-ol) (5-2): Potassium carbonate (6.22 g, 45 mmol) 
was added to diethylene glycol (50.0 mL, 528 mmol) in a 250 mL round-bottomed 
flask. Compound 5-1 (1.65 mL, 15.0 mmol) was added and the suspension was 
stirred at 80 oC under N2 for 16 hours. The orange solution was cooled to rt, 
diluted with 100 mL of cold 50% brine, and extracted with EtOAc (3 x 80 mL). 
The combined organic layers were washed with 5 x 100 mL saturated aq 
NaHCO3, dried over MgSO4 and solvents removed under reduced pressure to 
afford 5-2 (2.6789 g, 54%) as a viscous dark orange oil. 1H spectra matched 
known literature.244 1H NMR (CDCl3,500 MHz): 2.00 (brs, 2H), 3.68 (t, 2H, J = 4.5 
Hz), 3.71 (m, 2H), 3.77 (m, 4H), 4.21 (t, 2H, J = 4.5 Hz), 4.26 (t, 2H, J = 4.5 Hz), 







diyl))bis(oxy))bis(ethan-1-ol) (5-3): Compound 5-2 (2.68 g, 8.09 mmol) was 
dissolved in chloroform (22 mL) in a 250 mL round-bottomed flask. Potassium 
carbonate (1.17 g, 8.50 mmol) was added followed by bromine (0.4376 mL, 
8.4967 mmol) via addition funnel. The solution was then covered with foil and 
stirred in darkness for 2 h. Another 0.1 mL of bromine was added and the 
reaction stirred another h. A significant amount of gummy paste collected at the 
bottom of the flask over the course of the reaction which was occasionally broken 
up via spatula. The reaction was quenched with 50 mL of saturated Na2S2O3 
solution and then diluted with 50 mL of H2O and extracted with EtOAc (3 x 150 
mL). The combined organic layers were washed with 100 mL saturated Na2S2O3 
solution and 5 x 100 mL saturated aq NaHCO3 and then dried over MgSO4. 
Volatiles were removed under reduced pressure to afford compound 5-3 (2.83 g, 
85%) as a viscous orange-brown oil. 1H spectra matched known literature.244 1H 
NMR (CDCl3, 500 MHz): 2.07 (brs, 2H), 3.71 (m, 4H), 3.94 (m, 4H), 3.95 (m, 4H), 
4.30 (t, 2H, J = 4.7 Hz), 4.30 (t, 2H, J = 4.7 Hz), 6.78 (s, 1H), 8.22 (s, 1H) 
 
2,2'-((((4-amino-6-bromo-1,3-phenylene)bis(oxy))bis(ethane-2,1-
diyl))bis(oxy))bis(ethan-1-ol) (5-4): Compound 5-3 (2.83 g, 6.89 mmol) was 




bottomed flask. The solution was heated to 80 oC. Iron filings (2.70 g, 48.2 mmol) 
were added followed by anhydrous iron(III) chloride (0.190 g, 1.17 mmol). The 
solution was refluxed for 3 h at 130 oC and then cooled to rt. The reaction mixture 
was diluted with 50 mL of ethanol then filtered through celite. The pad of celite 
was then washed with 150 mL of ethanol. The solution was evaporated under 
reduced pressure and the crude product was subjected to flash chromatography 
(10:1 chloroform/methanol) to afford compound 5-4 (1.36 g, 52%) as a dark 
brown oil. 1H spectra matched known literature.244 1H NMR (500 MHz, CDCl3): δ 
2.93 (brs, 4H), 3.64 (t, 2H, J = 4.4 Hz), 3.70 (t, 2H, J = 4.6 Hz), 3.75 (t, 2H, J = 
4.5 Hz), 3.77 (t, 2H, J = 4.5 Hz), 3.82 (t, 2H, J = 4.6 Hz), 3.86 (t, 2H, J = 4.6 Hz), 
4.11 (t, 2H, J = 4.6 Hz), 4.17 (t, 2H, J = 4.4 Hz), 6.64 (s, 1H), 6.92 (s, 1H) 
 
5-bromo-2,4-bis(2-(2-((trimethylsilyl)oxy)ethoxy)ethoxy)aniline (5-5): 
Compound 5-4 was dissolved in THF (27 mL) in a 250 mL round-bottomed flask 
under N2 atmosphere. Dry triethylamine (1.020 mL, 7.3128 mmol) was added to 
the reaction mixture. The solution was cooled to 0 oC and then trimethylsilyl 
chloride was added dropwise, turning the solution from light brown to a cloudy 
slurry. The reaction was warmed to rt and then stirred overnight. The cloudy 




reduced pressure to afford crude 5-5 (1.42 g, 81%) as a brown viscous oil which 
was used without further purification. 
 
3-bromo-N,N-dimethylaniline (5-10): Aqueous H2SO4 (56 mL) was added to a 
stirred solution of aqueous formaldehyde (20.8 mL) in THF (250 mL) in a 500 mL 
round-bottomed flask. The mixture was cooled to 0 oC and stirred for another 10 
mins. Compound 5-9 (16 g, 93 mmol) was then added dropwise within 10 mins 
and the reaction mixture was stirred for an additional 10 mins. Solid NaBH4 (14.1 
g, 372 mmol) was slowly added portionwise within 30 mins while the temp was 
maintained at 0 oC. The resulting mixture was allowed to warm to rt and stirred 
for 1 h at 20 oC. Saturated aq NaHCO3 (350 mL) was then added and the 
reaction mixture was extracted with DCM (3 x 100 mL). The combined organic 
layer was dried over anhydrous MgSO4, filtered, and volatiles were evaporated 
under reduced pressure to afford compound 5-10 (14.0 g, 75%) as a yellowish 
liquid. 1H spectra matched known literature.259 1H NMR (500 MHz, CDCl3): δ 2.94 
(s, 6H), 6.62 (dd, 1H, J = 8.7, 1.9 Hz), 6.81-6.84 (m, 2H), 7.07 (t, 1H, J = 8.0 Hz 
 
4,4'-methylenebis(3-bromo-N,N-dimethylaniline) (5-11): Aqueous 
formaldehyde (3.26 mL, 43.3 mmol) was added dropwise to a solution of 5-10 




15 mins. The reaction mixture was then stirred at 90 oC for 1 h. Acetic acid was 
evaporated under reduced pressure and the residual acid was neutralized with 
saturated aqueous NaHCO3. The obtained residue was extracted with DCM (3 x 
50 mL). The combined organic layers were washed with water (2 x 50 mL) and 
brine (50 mL), dried over MgSO4 and filtered. The solvents were removed under 
reduced pressure, and the resulting red residue was subjected to flash 
chromatography with 3% EtOAc/hexanes as eluent to afford compound 5-11 
(8.18 g, 28%) as a white crystalline solid.1H spectra matched known literature.259 
1H NMR (500 MHz, CDCl3): δ 2.92 (s, 12H), 4.00 (s, 2H), 6.56-6.61 (m, 2H), 
6.83-6.87 (m, 2H), 6.94 (s, 2H) 
 
3,7-bis(dimethylamino)-5,5-dimethyldibenzo[b,e]silin-10(5H)-one (5-12): n-
butyllithium (1.6 M in hexanes, 23.6 mL, 37.8 mmol) was added dropwise within 
15 mins to a solution of compound 5-11 (6.00 g, 14.6 mmol) in dry THF (100 mL) 
in a 250 mL round-bottomed flask @ -78 oC under N2 atmosphere. The reaction 
mixture was stirred for 15 mins. Dichlorodimethylsilane (2.3 mL, 18.9 mmol) was 
then added dropwise over a period of 15 mins. The reaction mixture was stirred 
overnight while the temperature was allowed to rise to 20 oC. The reaction 
mixture was quenched by dropwise addition of aqueous HCl (30 mL) and 
subsequently neutralized with saturated aqueous NaHCO3 (100 mL).The mixture 




were removed under reduced pressure. The obtained air-sensitive blue-green 
crude product was diluted in acetone and cooled to 0 oC and potassium 
permanganate (6.90 g, 43.7 mmol) was added portion wise over a period of 2 h. 
the reaction was allowed to warm to 20 oC. when no SM was observed (usually 
after an additional 3 h as confirmed by TLC), generated manganese (IV) oxide 
was filtered through a pad of silica gel an the solid thoroughly washed with 
chloroform (~1.2 L). Mixed filtrates were concentrated under reduced pressure 
and the crude product was subjected to flash chromatography with 5:1:1 
hexanes/chloroform/EtOAc as eluent to afford 5-12 (4.72 g, 22%) as a yellow-
green solid. 1H spectra matched known literature.259 1H NMR (500 MHz, CDCl3): 
δ 0.48 (s, 6H), 3.11 (s, 12 H), 6.79-6.88 (m, 4H), 8.41 (d, 2H, J = 9.1 Hz)  
 
1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethan-1-ol (5-14): Sodium borohydride 
(0.100 g, 2.64 mmol) was added over 60 mins to a cold, stirring suspension of 
compound 5-13 (0.300 g, 1.43 mmol) in methanol (10 mL) in a 100 mL round-
bottomed flask, maintaining a temperature of 5–15 oC from external cooling. 
Stirring was continued for 3 h and then the reaction was quenched with saturated 
NH4Cl solution (20 mL). The resulting suspension was extracted with DCM (3 x 
15 mL) and the combined extracts were washed with brine (25 mL), dried with 
MgSO4, and the solvent was evaporated under reduced pressure to yield 




known literature.258  1H NMR (500 MHz, CDCl3): δ 1.54 (d, 3H, J = 6.3 Hz), 5.46 
(qd, 1 H, J = 12.6, 9.0, and 2.7 Hz), 6.11 (d, 2H, J = 2.5 Hz), 7.26 (d, 1H, J = 5.6), 
7.46 (s, 1H).  
 
1-(tert-butyl) 5-(1-(6-nitrobenzo[d][1,3]dioxol-5-yl)ethyl) (((9H-fluoren-9-
yl)methoxy)carbonyl)glutamate (5-15): Compound 5-17 (0.100 g, 0.235 mmol), 
DMAP (0.0029 g, 0.024 mmol), and EDC (0.0438 g, 0.282 mmol) in DCM (1 mL) 
were stirred for 20 min at rt in a 50 mL round bottomed flask. Compound 5-14 
(0.0500 g, 0.235 mmol) was added to the reaction mixture and the resulting 
mixture was stirred overnight in the dark. Solvents were evaporated under 
reduced pressure and the crude product was purified via flash chromatography 
with 10% Acetone/hexanes as eluent to afford compound 5-15 (0.0835 g, 57%) 
as a pale yellow solid. 1H NMR (500 MHz, CDCl3): δ 1.47 (s, 9H), 1.54 (s, 2H), 
1.59 (dd, 3H, J = 6.42, 3.5 Hz), 1.91 (m, 1H), 2.18, (m, 1H), 2.42 (m, 2H), 4.21 (q, 
1H, J = 7.1 Hz), 4.29 (m, 1H), 4.39 (bs, 2H), 5.37 (d, 1H, J = 8.1), 6.03 (d, 1H, J = 
16.9 Hz), 6.07 (s, 1H), 6.38 (m, 1H), 7.00 (d, 1H, J = 4.1 Hz), 7.31 (m, 2H,), 7.40 







nitrobenzo[d][1,3]dioxol-5-yl)ethoxy)-5-oxopentanoic acid (5-16): Compound 
5-15 (0.0214 g, 0.0346 mmol) was dissolved in 1:1 DCM and TFA (1 mL) in a 25 
mL round-bottomed flask and stirred for 1.5 h. The reaction was diluted with 20 
mL of ice water and neutralized with saturated NaHCO3 solution (10 mL). The 
resulting precipitate was taken up in DCM and subjected to column 
chromatography with 20% EtOAc/hexanes as eluent to afford 5-16 (0.0037g, 
19%) as a pale-yellow solid. 1H spectra matched known literature.257 1H NMR 
(500 MHz, CDCl3): δ 1.24 (s, 1H), 1.59 (dd, 3H, J = 6.4, 2.7 Hz), 1.95 (m, 1H), 
2.21 (m, 1H), 2.45 (m, 2H), 4.21 (q, 1H, J = 7.1 Hz), 4.40 (t, 3H, J = 7.5 Hz), 5.38 
(broad s, 1H), 6.04 (d, 1H, J = 15.7 Hz), 6.07 (s, 1H), 6.39 (q, 1H, J = 6.4 Hz), 
7.00 (s, 1H), 7.32 (m, 2H), 7.40 (m, 2H), 7.45 (d, 1H, J = 9.6 Hz), 7.58 (q, 2H, J = 





CHAPTER SIX : 
CONCLUSIONS AND FUTURE WORK 
The main projects associated with this dissertation represent the potential 
to further elucidate critical mechanisms associated with myo-inositol and serine 
phospholipid metabolism. The synthesis of derivative 2-1 has yielded exciting 
results so far that show the ability to infiltrate the native biomachinery used in 
yeast myo-inositol lipid metabolism. One of the weaknesses of these studies is 
the difficulty in replicating the results in mammalian cells. Studies were previously 
conducted and yielded promising results, but proved very difficult to reproduce 
(Figure 6-1).  
Even though yeast have very similar methods of PIPn and InsP synthesis 
to humans, having the ability to robustly label mammalian cells represents an 
exciting avenue of therapeutic discovery. As stated before, myo-inositol is at the 
helm of an extremely complex and essential cell signaling pathway which 
regulates cellular growth amongst other things. Devising and completing 
derivatives such as 2-17 and 2-18 or optimizing conditions to be compatible with 
cell lines of interest, specifically cancer cells, present an exciting opportunity for 
development of new therapies. In yeast cells, it has been previously established 
that the IPC lipid pathway is essential for yeast cell viability. The C2 hydroxyl is 
pivotal in this pathway as that is where all mannosyl moieties are attached to 
complete MIPC biosynthesis.217,222-223 Compounds 2-17 and 2-18 once again 









antifungals since mammalian cells do not have a comparable sphingolipid 
synthesis pathway.  
 
 
Figure 6-2. Potential mechanisms of probing phospholipid synthase and 
transferase enzymes based on PS synthase inhibition studies. 
 
Irreversible labeling of the PS synthase active site also represents some 
similar possibilities in developing antifungals, but it also represents an 
opportunity to probe the mechanism of the CDP-DAG pathway further. All 
eukaryotes utilize this pathway in some fashion to produce different classes of 
phospholipids. Developing specific trapping derivatives of these headgroups 
(glycerol, choline, serine, myo-inositol etc.) according to their utilization in CDP-
DAG pathways phospholipid biosynthesis could be a way to validate this 
synthase mechanism across all phospholipids (Figure 6-2). For example, 
bromocholine derivatives can be used in a similar fashion as propargylcholine 
derivatives were used by Jao and co-workers.131 Instead of the propargyl group 
being used as a click handle, the bromine acts as an electrophilic trap similar to 
the above studies with serine and cysteine. This methodology could open up 




in targeting specific CDP-DAG pathway substrates that do not overlap amongst 
cell types. 
The research represented in this dissertation is indicative of strong 
fundamentals of chemical biology. The chemistry aspect is utilized to synthesize 
relevant molecules to answer critical biology related questions. Bioorthogonal 
chemistry offers a robust suite of chemistry that can be utilized to probe 
biological systems mechanistically with minimal cellular perturbation. The biology 
aspect is utilized in exploiting cellular systems of interest that are asking the 
questions. Basic knowledge of cellular growth kinetics, cellular metabolism, and 
substrate utilization is critical in developing the correct experiments needed to 
validate the hypotheses to be answered chemically. The data presented and 
techniques utilized reveal a deep understanding of chemistry and biology as well 










1. Kılbaş, B.; Balci, M., Recent advances in inositol chemistry: synthesis and 
applications. Tetrahedron 2011, 67 (13), 2355-2389. 
2. Best, M. D.; Zhang, H.; Prestwich, G. D., Inositol polyphosphates, 
diphosphoinositol polyphosphates and phosphatidylinositol polyphosphate lipids: 
Structure, synthesis, and development of probes for studying biological activity. 
Nat. Prod. Rep. 2010, 27 (10), 1403-1430. 
3. Jagdhane, R. C.; Shashidhar, M. S., Orthogonally Protected 
Cyclohexanehexols by a “One Reaction – One Product” Approach: Efficient 
Access to Cyclitols and Their Analogs. Eur. J. Org. Chem. 2010, 2010 (15), 
2945-2953. 
4. Potter, B. V. L.; Lampe, D., Chemistry of Inositol Lipid Mediated Cellular 
Signaling. Angew. Chem., Int. Ed. Engl. 1995, 34 (18), 1933-1972. 
5. Devaraj, S.; Shashidhar, M. S.; Dixit, S. S., Chelation controlled 
regiospecific O-substitution of myo-inositol orthoesters: convenient access to 
orthogonally protected myo-inositol derivatives. Tetrahedron 2005, 61 (3), 529-
536. 
6. Godage, H. Y.; Riley, A. M.; Woodman, T. J.; Thomas, M. P.; Mahon, M. 
F.; Potter, B. V. L., Regioselective Opening of myo-Inositol Orthoesters: 
Mechanism and Synthetic Utility. J. Org. Chem. 2013, 78 (6), 2275-2288. 
7. Lee, H. W.; Kishi, Y., Synthesis of mono- and unsymmetrical bis-




8. Sarmah, M. P.; Shashidhar, M. S., Sulfonate protecting groups.: Improved 
synthesis of scyllo-inositol and its orthoformate from myo-inositol. Carbohydr. 
Res. 2003, 338 (9), 999-1001. 
9. Sarmah, M. P.; Shashidhar, M. S.; Sureshan, K. M.; Gonnade, R. G.; 
Bhadbhade, M. M., Sulfonate protecting groups. Synthesis of O- and C-
methylated inositols: d- and l-ononitol, d- and l-laminitol, mytilitol and scyllo-
inositol methyl ether. Tetrahedron 2005, 61 (18), 4437-4446. 
10. Sureshan, K. M.; Shashidhar, M. S., Sulfonate protecting groups. 
Regioselective O-sulfonylation of myo-inositol orthoesters. Tetrahedron Lett. 
2001, 42 (16), 3037-3039. 
11. Sureshan, K. M.; Shashidhar, M. S., Regioselective O-acylation of myo-
inositol 1,3,5-orthoesters: the role of acyl migration. Tetrahedron Lett. 2000, 41 
(21), 4185-4188. 
12. Sureshan, K. M.; Shashidhar, M. S.; Praveen, T.; Gonnade, R. G.; 
Bhadbhade, M. M., Sulfonate protecting groups. Regioselective sulfonylation of 
myo-inositol orthoesters—improved synthesis of precursors of d- and l-myo-
inositol 1,3,4,5-tetrakisphosphate, myo-inositol 1,3,4,5,6-pentakisphosphate and 
related derivatives. Carbohydr. Res. 2002, 337 (24), 2399-2410. 
13. Holub, B. J., Metabolism and Function of myo-Inositol and Inositol 
Phospholipids. Annu. Rev. Nutr. 1986, 6 (1), 563-597. 
14. Berridge, M. J.; Irvine, R. F., Inositol phosphates and cell signalling. 




15. Brunet, A.; Bonni, A.; Zigmond, M. J.; Lin, M. Z.; Juo, P.; Hu, L. S.; 
Anderson, M. J.; Arden, K. C.; Blenis, J.; Greenberg, M. E., Akt Promotes Cell 
Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor. Cell 
1999, 96 (6), 857-868. 
16. Larner, J., D-Chiro-Inositol and Its Functional Role in Insulin Action and its 
Deficit in Insulin Resistance. Int. J. Exp. Diabet. Res. 2002, 3 (1). 
17. Berridge, M. J.; Lipp, P.; Bootman, M. D., The versatility and universality 
of calcium signalling. Nat. Rev. Mol. Cell Biol. 2000, 1 (1), 11-21. 
18. Streb, H.; Irvine, R. F.; Berridge, M. J.; Schultz, I., Release of Ca2+ from a 
nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-
trisphosphate. Nature 1983, 306 (5938), 67-69. 
19. Di Paolo, G.; De Camilli, P., Phosphoinositides in cell regulation and 
membrane dynamics. Nature 2006, 443 (7112), 651-657. 
20. Majerus, P. W.; York, J. D., Phosphoinositide phosphatases and disease. 
J. Lipid Res. 2009, 50 (Supplement), S249-S254. 
21. Vucenik, I.; Shamsuddin, A. M., Protection Against Cancer by Dietary IP6 
and Inositol. Nutr. Cancer 2006, 55 (2), 109-125. 
22. Schneider, S., Inositol transport proteins. FEBS Lett. 2015, 589 (10), 
1049-1058. 
23. Kwon, H. M.; Yamauchi, A.; Uchida, S.; Preston, A. S.; Garcia-Perez, A.; 




cotransporter, a hypertonicity stress protein. J. Biol. Chem. 1992, 267 (9), 6297-
301. 
24. Yamauchi, A.; Nakanishi, T.; Takamitsu, Y.; Sugita, M.; Imai, E.; Noguchi, 
T.; Fujiwara, Y.; Kamada, T.; Ueda, N., In vivo osmoregulation of Na/myo-inositol 
cotransporter mRNA in rat kidney medulla. J. Am. Soc. Nephrol. 1994, 5 (1), 62-
7. 
25. Berry, G. T.; Mallee, J. J.; Kwon, H. M.; Rim, J. S.; Mulla, W. R.; Muenke, 
M.; Spinner, N. B., The human osmoregulatory Na+/myo-inositol cotransporter 
gene (SLC5A3): molecular cloning and localization to chromosome 21. 
Genomics 1995, 25 (2), 507-513. 
26. McVeigh, K. E.; Mallee, J. J.; Lucente, A.; Barnoski, B. L.; Wu, S.; Berry, 
G. T., Murine chromosome 16 telomeric region, homologous with human 
chromosome 21q22, contains the osmoregulatory Na<sup>+</sup>/myo-inositol 
cotransporter (SLC5A3) gene. Cytogenet. Genome Res. 2000, 88 (1-2), 153-158. 
27. Hager, K.; Hazama, A.; Kwon, H. M.; Loo, D. D. F.; Handler, J. S.; Wright, 
E. M., Kinetics and specificity of the renal Na+/myo-inositol cotransporter 
expressed in Xenopus Oocytes. The Journal of Membrane Biology 1995, 143 (2), 
103-113. 
28. Coady, M. J.; Wallendorff, B.; Gagnon, D. G.; Lapointe, J.-Y., Identification 





29. Uldry, M.; Ibberson, M.; Horisberger, J.-D.; Chatton, J.-Y.; Riederer, B. M.; 
Thorens, B., Identification of a mammalian H+-myo-inositol symporter expressed 
predominantly in the brain. The EMBO Journal 2001, 20 (16), 4467-4477. 
30. Nikawa, J.; Tsukagoshi, Y.; Yamashita, S., Isolation and characterization 
of two distinct myo-inositol transporter genes of Saccharomyces cerevisiae. J. 
Biol. Chem. 1991, 266 (17), 11184-11191. 
31. Miyashita, M.; Shugyo, M.; Nikawa, J.-I., Mutational analysis and 
localization of the inositol transporters of Saccharomyces cerevisiae. J. Biosci. 
Bioeng. 2003, 96 (3), 291-297. 
32. Jin, J. H.; Seyfang, A., High-affinity myo-inositol transport in Candida 
albicans: substrate specificity and pharmacology. Microbiology 2003, 149 (12), 
3371-3381. 
33. Holub, B. J.; Kuksis, A.; Thompson, W., Molecular species of mono-, di-, 
and triphosphoinositides of bovine brain. J. Lipid Res. 1970, 11 (6), 558-564. 
34. Holub, B. J.; Kuksis, A., Structural and Metabolic Interrelationships Among 
Glycerophosphatides of Rat Liver In Vivo. Can. J. Biochem. 1971, 49 (12), 1347-
1356. 
35. Schneiter, R.; Brügger, B.; Sandhoff, R.; Zellnig, G.; Leber, A.; Lampl, M.; 
Athenstaedt, K.; Hrastnik, C.; Eder, S.; Daum, G.; Paltauf, F.; Wieland, F. T.; 
Kohlwein, S. D., Electrospray Ionization Tandem Mass Spectrometry (Esi-Ms/Ms) 
Analysis of the Lipid Molecular Species Composition of Yeast Subcellular 




Species En Route to the Plasma Membrane. The Journal of Cell Biology 1999, 
146 (4), 741-754. 
36. Luthra, M. G.; Sheltawy, A., The fractionation of phosphatidylinositol into 
molecular species by thin-layer chromatography on silver nitrate-impregnated 
silica gel. Biochem. J. 1972, 126 (5), 1231-1239. 
37. Laussmann, T.; Hansen, A.; Reddy, K. M.; Reddy, K. K.; Falck, J. R.; 
Vogel, G., Diphospho-myo-inositol phosphates in Dictyostelium and 
Polysphondylium: identification of a new bisdiphospho-myo-inositol 
tetrakisphosphate. FEBS Lett. 1998, 426 (1), 145-150. 
38. Lin, H.; Fridy, P. C.; Ribeiro, A. A.; Choi, J. H.; Barma, D. K.; Vogel, G.; 
Falck, J. R.; Shears, S. B.; York, J. D.; Mayr, G. W., Structural Analysis and 
Detection of Biological Inositol Pyrophosphates Reveal That the Family of 
VIP/Diphosphoinositol Pentakisphosphate Kinases Are 1/3-Kinases. J. Biol. 
Chem. 2009, 284 (3), 1863-1872. 
39. Stephens, L.; Radenberg, T.; Thiel, U.; Vogel, G.; Khoo, K. H.; Dell, A.; 
Jackson, T. R.; Hawkins, P. T.; Mayr, G. W., The detection, purification, structural 
characterization, and metabolism of diphosphoinositol pentakisphosphate(s) and 
bisdiphosphoinositol tetrakisphosphate(s). J. Biol. Chem. 1993, 268 (6), 4009-15. 
40. Albert, C.; Safrany, T. S.; Bembenek, E. M.; Reddy, K. M.; Reddy, K. K.; 
Falck, J. R.; Brocker, M.; Shears, B. S.; Mayr, W. G., Biological variability in the 
structures of diphosphoinositol polyphosphates in Dictyostelium discoideum and 




41. Shears, S. B., Diphosphoinositol Polyphosphates: Metabolic Messengers? 
Mol. Pharmacol. 2009, 76 (2), 236-252. 
42. Paulus, H.; Kennedy, E. P., The Enzymatic Synthesis of Inositol 
Monophosphatide. J. Biol. Chem. 1960, 235 (5), 1303-1311. 
43. Bleasdale, J. E.; Wallis, P.; MacDonald, P. C.; Johnston, J. M., 
Characterization of the forward and reverse reactions catalyzed by CDP-
diacylglycerol: Inositol transferase in rabbit lung tissue. Biochim. Biophys. Acta, 
Lipids and Lipid Metab. 1979, 575 (1), 135-147. 
44. Kim, Yeun J.; Guzman-Hernandez, Maria L.; Balla, T., A Highly Dynamic 
ER-Derived Phosphatidylinositol-Synthesizing Organelle Supplies 
Phosphoinositides to Cellular Membranes. Dev. Cell 21 (5), 813-824. 
45. Henry, S. A.; Atkinson, K. D.; Kolat, A. I.; Culbertson, M. R., Growth and 
metabolism of inositol-starved Saccharomyces cerevisiae. J. Bacteriol. 1977, 130 
(1), 472-484. 
46. Henry, S. A.; Gaspar, M. L.; Jesch, S. A., The response to inositol: 
Regulation of glycerolipid metabolism and stress response signaling in yeast. 
Chem. Phys. Lipids 2014, 180, 23-43. 
47. Majumder, A. L.; Johnson, M. D.; Henry, S. A., 1l-myo-Inositol-1-
phosphate synthase. Biochim. Biophys. Acta, Lipids and Lipid Metab. 1997, 1348 
(1–2), 245-256. 
48. Villa-García, M.; Choi, M.; Hinz, F.; Gaspar, M.; Jesch, S.; Henry, S., 




implicates lipid metabolism in stress response signaling. Mol. Genet. Genomics 
2011, 285 (2), 125-149. 
49. Azab, A. N.; He, Q.; Ju, S.; Li, G.; Greenberg, M. L., Glycogen synthase 
kinase-3 is required for optimal de novo synthesis of inositol. Mol. Microbiol. 
2007, 63 (4), 1248-1258. 
50. G M Carman, a.; Henry, S. A., Phospholipid Biosynthesis in Yeast. Annu. 
Rev. Biochem. 1989, 58 (1), 635-667. 
51. Henry, S. A.; Patton-Vogt, J. L., Genetic Regulation of Phospholipid 
Metabolism: Yeast as a Model Eukaryote. Prog. Nucleic Acid Res. Mol. Biol. 
1998, 61, 133-179. 
52. Hanson, B. A.; Lester, R. L., The extraction of inositol-containing 
phospholipids and phosphatidylcholine from Saccharomyces cerevisiae and 
Neurospora crassa. J. Lipid Res. 1980, 21 (3), 309-15. 
53. Pasari, S. Synthetic Studies of Azido-Inositols and Inositol-based Glycans. 
Dissertation, National University of Singapore, 2012. 
54. Carman, G. M.; Henry, S. A., Phospholipid biosynthesis in the yeast 
Saccharomyces cerevisiae and interrelationship with other metabolic processes. 
Prog. Lipid Res. 1999, 38 (5–6), 361-399. 
55. Hirsch, J. P.; Henry, S. A., Expression of the Saccharomyces cerevisiae 
inositol-1-phosphate synthase (INO1) gene is regulated by factors that affect 




56. Bailis, A. M.; Poole, M. A.; Carman, G. M.; Henry, S. A., The membrane-
associated enzyme phosphatidylserine synthase is regulated at the level of 
mRNA abundance. Mol. Cell. Biol. 1987, 7 (1), 167-176. 
57. Shen, H.; Dowhan, W., Regulation of Phospholipid Biosynthetic Enzymes 
by the Level of CDP-Diacylglycerol Synthase Activity. J. Biol. Chem. 1997, 272 
(17), 11215-11220. 
58. Gaynor, P. M.; Gill, T.; Toutenhoofd, S.; Summers, E. F.; McGraw, P.; 
Homann, M. J.; Henry, S. A.; Carman, G. M., Regulation of 
phosphatidylethanolamine methyltransferase and phospholipid methyltransferase 
by phospholipid precursors in Saccharomyces cerevisiae. Biochimica et 
Biophysica Acta (BBA) - Gene Structure and Expression 1991, 1090 (3), 326-
332. 
59. Shen, H.; Dowhan, W., Regulation of Phosphatidylglycerophosphate 
Synthase Levels inSaccharomyces cerevisiae. J. Biol. Chem. 1998, 273 (19), 
11638-11642. 
60. Han, S.-H.; Han, G.-S.; Iwanyshyn, W. M.; Carman, G. M., Regulation of 
the PIS1-encoded Phosphatidylinositol Synthase in Saccharomyces cerevisiae 
by Zinc. J. Biol. Chem. 2005, 280 (32), 29017-29024. 
61. Lykidis, A.; Jackson, P. D.; Rock, C. O.; Jackowski, S., The Role of CDP-
Diacylglycerol Synthetase and Phosphatidylinositol Synthase Activity Levels in 





62. Antonsson, B. E.; Klig, L. S., Candida albicans phosphatidylinositol 
synthase has common features with both Saccharomyces cerevisiae and 
mammalian phosphatidylinositol synthases. Yeast 1996, 12 (5), 449-456. 
63. Cantley, L. C., The Phosphoinositide 3-Kinase Pathway. Science 2002, 
296 (5573), 1655-1657. 
64. Itoh, T.; De Camilli, P., BAR, F-BAR (EFC) and ENTH/ANTH domains in 
the regulation of membrane–cytosol interfaces and membrane curvature. 
Biochim. Biophys. Acta, Mol. and Cell Bio. of Lipids 2006, 1761 (8), 897-912. 
65. Kutateladze, T. G., Mechanistic similarities in docking of the FYVE and PX 
domains to phosphatidylinositol 3-phosphate containing membranes. Prog. Lipid 
Res. 2007, 46 (6), 315-327. 
66. Vivanco, I.; Sawyers, C. L., The phosphatidylinositol 3-Kinase-AKT 
pathway in human cancer. Nat. Rev. Cancer 2002, 2 (7), 489-501. 
67. Várnai, P.; Bondeva, T.; Tamás, P.; Tóth, B.; Buday, L.; Hunyady, L.; 
Balla, T., Selective cellular effects of overexpressed pleckstrin-homology 
domains that recognize PtdIns(3,4,5)P3 suggest their interaction with protein 
binding partners. J. Cell Sci. 2005, 118 (20), 4879-4888. 
68. Lietzke, S. E.; Bose, S.; Cronin, T.; Klarlund, J.; Chawla, A.; Czech, M. P.; 
Lambright, D. G., Structural Basis of 3-Phosphoinositide Recognition by 
Pleckstrin Homology Domains. Mol. Cell 2000, 6 (2), 385-394. 
69. Rameh, L. E.; Cantley, L. C., The Role of Phosphoinositide 3-Kinase Lipid 




70. McCubrey, J. A.; Steelman, L. S.; Abrams, S. L.; Lee, J. T.; Chang, F.; 
Bertrand, F. E.; Navolanic, P. M.; Terrian, D. M.; Franklin, R. A.; D’Assoro, A. B.; 
Salisbury, J. L.; Mazzarino, M. C.; Stivala, F.; Libra, M., Roles of the 
RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and 
drug resistance. Adv. Enzyme Regul. 2006, 46 (1), 249-279. 
71. Hennessy, B. T.; Smith, D. L.; Ram, P. T.; Lu, Y.; Mills, G. B., Exploiting 
the PI3K/AKT Pathway for Cancer Drug Discovery. Nat. Rev. Drug Discovery 
2005, 4 (12), 988-1004. 
72. Brunn, G. J.; Williams, J.; Sabers, C.; Wiederrecht, G.; Lawrence, J. C.; 
Abraham, R. T., Direct inhibition of the signaling functions of the mammalian 
target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and 
LY294002. The EMBO journal 1996, 15 (19), 5256-5267. 
73. Li, J.; Simpson, L.; Takahashi, M.; Miliaresis, C.; Myers, M. P.; Tonks, N.; 
Parsons, R., The PTEN/MMAC1 Tumor Suppressor Induces Cell Death That Is 
Rescued by the AKT/Protein Kinase B Oncogene. Cancer Res. 1998, 58 (24), 
5667-5672. 
74. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; 
Greenberg, M. E., Akt Phosphorylation of BAD Couples Survival Signals to the 
Cell-Intrinsic Death Machinery. Cell 1997, 91 (2), 231-241. 
75. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; 
Stanbridge, E.; Frisch, S.; Reed, J. C., Regulation of Cell Death Protease 




76. Diehl, J. A.; Cheng, M.; Roussel, M. F.; Sherr, C. J., Glycogen synthase 
kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes 
Dev. 1998, 12 (22), 3499-3511. 
77. Gómez-Fernández, J. C.; Corbalán-García, S., Diacylglycerols, multivalent 
membrane modulators. Chem. Phys. Lipids 2007, 148 (1), 1-25. 
78. Irvine, R. F.; Schell, M. J., Back in the water: the return of the inositol 
phosphates. Nat. Rev. Mol. Cell Biol. 2001, 2 (5), 327-338. 
79. Shears, S. B., Assessing the omnipotence of inositol hexakisphosphate. 
Cell. Signal. 2001, 13 (3), 151-158. 
80. Quignard, J. F.; Rakotoarisoa, L.; Mironneau, J.; Mironneau, C., 
Stimulation of L-type Ca2+ channels by inositol pentakis- and hexakisphosphates 
in rat vascular smooth muscle cells. The J. of Physiol. 2003, 549 (3), 729-737. 
81. Campbell, S.; Fisher, R. J.; Towler, E. M.; Fox, S.; Issaq, H. J.; Wolfe, T.; 
Phillips, L. R.; Rein, A., Modulation of HIV-like particle assembly in vitro by 
inositol phosphates. Proc. Natl. Acad. Sci. 2001, 98 (19), 10875-10879. 
82. Komander, D.; Fairservice, A.; Deak, M.; Kular, G. S.; Prescott, A. R.; 
Peter Downes, C.; Safrany, S. T.; Alessi, D. R.; van Aalten, D. M. F., Structural 
insights into the regulation of PDK1 by phosphoinositides and inositol 
phosphates. EMBO (Eur Mol Biol Organ) J 2004, 23 (20), 3918-3928. 
83. Caffrey, J. J.; Darden, T.; Wenk, M. R.; Shears, S. B., Expanding 
coincident signaling by PTEN through its inositol 1,3,4,5,6-pentakisphosphate 3-




84. Maffucci, T.; Piccolo, E.; Cumashi, A.; Iezzi, M.; Riley, A. M.; Saiardi, A.; 
Godage, H. Y.; Rossi, C.; Broggini, M.; Iacobelli, S.; Potter, B. V. L.; Innocenti, 
P.; Falasca, M., Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by 
Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. 
Cancer Res. 2005, 65 (18), 8339-8349. 
85. Piccolo, E.; Vignati, S.; Maffucci, T.; Innominato, P. F.; Riley, A. M.; Potter, 
B. V.; Pandolfi, P. P.; Broggini, M.; Iacobelli, S.; Innocenti, P.; Falasca, M., 
Inositol pentakisphosphate promotes apoptosis through the PI 3-K//Akt pathway. 
Oncogene 2004, 23 (9), 1754-1765. 
86. Abou-Saleh, H.; Pathan, A. R.; Daalis, A.; Hubrack, S.; Abou-Jassoum, H.; 
Al-Naeimi, H.; Rusch, N. J.; Machaca, K., Inositol 1,4,5-Trisphosphate (IP3) 
Receptor Up-regulation in Hypertension Is Associated with Sensitization of Ca2+ 
Release and Vascular Smooth Muscle Contractility. J. Biol. Chem. 2013, 288 
(46), 32941-32951. 
87. Gaastra, W.; Josephsen, J., Radiolabeling of DNA with the Klenow 
Fragment of DNA Polymerase. In Nucleic Acids, Walker, J. M., Ed. Humana 
Press: Totowa, NJ, 1984; pp 273-276. 
88. Sheardown, S., Radiolabelling Nucleic Acids: Generating DNA Probes by 
Random Priming. In eLS, John Wiley & Sons, Ltd: 2001. 
89. Mathew, C. G. P., Radiolabeling of DNA by Nick Translation. In Nucleic 




90. Huang, C.; Yu, Y.-T., Synthesis and Labeling of RNA In Vitro. In Current 
Protocols in Molecular Biology, John Wiley & Sons, Inc.: 2001. 
91. Adachi, H.; Yu, Y.-T., Purification of Radiolabeled RNA Products Using 
Denaturing Gel Electrophoresis. In Current Protocols in Molecular Biology, John 
Wiley & Sons, Inc.: 2001. 
92. Plotch, S. J.; Krug, R. M., Influenza virion transcriptase: synthesis in vitro 
of large, polyadenylic acid-containing complementary RNA. J. Virol. 1977, 21 (1), 
24-34. 
93. Montelaro, R. C.; Rueckert, R. R., Radiolabeling of proteins and viruses in 
vitro by acetylation with radioactive acetic anhydride. J. Biol. Chem. 1975, 250 
(4), 1413-1421. 
94. Schumacher, T. N. M.; Tsomides, T. J., In Vitro Radiolabeling of Peptides 
and Proteins. In Current Protocols in Protein Science, John Wiley & Sons, Inc.: 
2001. 
95. Patel, A. C.; Matthewson, S. R., Radiolabeling of Peptides and Proteins. In 
Molecular Biomethods Handbook, Rapley, R.; Walker, J. M., Eds. Humana 
Press: Totowa, NJ, 1998; pp 411-411. 
96. Kalinich, J. F.; McClain, D. E., An in vitro method for radiolabeling proteins 
with 35S. Anal. Biochem. 1992, 205 (2), 208-212. 
97. Pérochon, E.; Leray, C.; Crémel, G.; Hubert, P., Radiolabeling of the 
Lipids of Chinese Hamster Ovary Cells with the Probe [3-(Trifluoromethyl)-3- (m-




98. Schneider, J. C.; Roessler, P., Radiolabeling Studies of Lipids and Fatty 
Acids in Nannochloropsis (Eustigmatophyceae), an Oleaginous Marine Algae. J. 
Phycol. 1994, 30 (4), 594-598. 
99. Jones, D. R.; Ramirez, I. B.-R.; Lowe, M.; Divecha, N., Measurement of 
phosphoinositides in the zebrafish Danio rerio. Nat. Protocols 2013, 8 (6), 1058-
1072. 
100. Sahai, P.; Chawla, M.; Vishwakarma, R. A., 13C Labelling and 
electrospray mass spectrometry reveal a de novo route for inositol biosynthesis 
in Leishmania donovani parasite. J. Chem. Soc., Perkin Trans. 1 2000,  (8), 
1283-1290. 
101. Baskin, J. M.; Prescher, J. A.; Laughlin, S. T.; Agard, N. J.; Chang, P. V.; 
Miller, I. A.; Lo, A.; Codelli, J. A.; Bertozzi, C. R., Copper-free click chemistry for 
dynamic in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (43), 16793-
16797. 
102. Hong, V.; Steinmetz, N. F.; Manchester, M.; Finn, M. G., Labeling Live 
Cells by Copper-Catalyzed Alkyne−Azide Click Chemistry. Bioconjugate Chem. 
2010, 21 (10), 1912-1916. 
103. Laughlin, S. T.; Agard, N. J.; Baskin, J. M.; Carrico, I. S.; Chang, P. V.; 
Ganguli, A. S.; Hangauer, M. J.; Lo, A.; Prescher, J. A.; Bertozzi, C. R., Metabolic 
Labeling of Glycans with Azido Sugars for Visualization and Glycoproteomics. In 




104. Sawa, M.; Hsu, T.-L.; Itoh, T.; Sugiyama, M.; Hanson, S. R.; Vogt, P. K.; 
Wong, C.-H., Glycoproteomic probes for fluorescent imaging of fucosylated 
glycans in vivo. Proc. Natl. Acad. Sci. 2006, 103 (33), 12371-12376. 
105. Saxon, E.; Bertozzi, C. R., Cell Surface Engineering by a Modified 
Staudinger Reaction. Science 2000, 287 (5460), 2007-2010. 
106. Dyukarev, E. A.; Knyazeva, A. G., Model of detonation of lead azide 
(Pb(N3)2) with regard to fracture. Int. J. Frac. 1999, 100 (2), 197-205. 
107. Scriven, E. F. V.; Turnbull, K., Azides: their preparation and synthetic 
uses. Chemical Reviews 1988, 88 (2), 297-368. 
108. Staudinger, H.; Meyer, J., Über neue organische Phosphorverbindungen 
III. Phosphinmethylenderivate und Phosphinimine. Helv. Chim. Acta 1919, 2 (1), 
635-646. 
109. Sletten, E. M.; Bertozzi, C. R., Bioorthogonal Chemistry: Fishing for 
Selectivity in a Sea of Functionality. Angew. Chem., Int. Ed. 2009, 48 (38), 6974-
6998. 
110. Huisgen, R., Proceedings of the Chemical Society. October 1961. 
Proceedings of the Chemical Society 1961,  (October), 357-396. 
111. Zhou, Z.; Fahrni, C. J., A Fluorogenic Probe for the Copper(I)-Catalyzed 
Azide−Alkyne Ligation Reaction:  Modulation of the Fluorescence Emission via 




112. Kolb, H. C.; Finn, M. G.; Sharpless, K. B., Click Chemistry: Diverse 
Chemical Function from a Few Good Reactions. Angew. Chem., Int. Ed. 2001, 
40 (11), 2004-2021. 
113. Glazer, A. N., Specific Chemical Modification of Proteins. Annu. Rev. 
Biochem. 1970, 39 (1), 101-130. 
114. Dixon, H. B. F., N-terminal modification of proteins—a review. J. Protein 
Chem. 1984, 3 (1), 99-108. 
115. Cennamo, C.; Carafoli, B.; Bonetti, E. P., Non-enzymatic Transamination 
between Peptides and Pyridoxal. Isolation of the 2,4-Dinitrophenylhydrazones of 
Some Ketopeptides. J. Am. Chem. Soc. 1956, 78 (14), 3523-3527. 
116. Dixon, H., Transamination of peptides. Biochem. J. 1964, 92 (3), 661-666. 
117. Dawson, P.; Muir, T.; Clark-Lewis, I.; Kent, S., Synthesis of proteins by 
native chemical ligation. Science 1994, 266 (5186), 776-779. 
118. Griffin, B. A.; Adams, S. R.; Tsien, R. Y., Specific Covalent Labeling of 
Recombinant Protein Molecules Inside Live Cells. Science 1998, 281 (5374), 
269-272. 
119. Adams, S. R.; Campbell, R. E.; Gross, L. A.; Martin, B. R.; Walkup, G. K.; 
Yao, Y.; Llopis, J.; Tsien, R. Y., New Biarsenical Ligands and Tetracysteine 
Motifs for Protein Labeling in Vitro and in Vivo:  Synthesis and Biological 




120. Albert Griffin, B.; Adams, S. R.; Jones, J.; Tsien, R. Y., Fluorescent 
labeling of recombinant proteins in living cells with FlAsH. Methods Enzymol. 
2000, 327, 565-578. 
121. Martin, B. R.; Giepmans, B. N. G.; Adams, S. R.; Tsien, R. Y., Mammalian 
cell-based optimization of the biarsenical-binding tetracysteine motif for improved 
fluorescence and affinity. Nat Biotech 2005, 23 (10), 1308-1314. 
122. Tsien, R. Y., The Green Fluorescent Protein. Annu. Rev. Biochem. 1998, 
67 (1), 509-544. 
123. Shaner, N. C.; Steinbach, P. A.; Tsien, R. Y., A guide to choosing 
fluorescent proteins. Nat Meth 2005, 2 (12), 905-909. 
124. Halo, T. L.; Appelbaum, J.; Hobert, E. M.; Balkin, D. M.; Schepartz, A., 
Selective Recognition of Protein Tetraserine Motifs with a Cell-Permeable, Pro-
fluorescent Bis-boronic Acid. J. Am. Chem. Soc. 2009, 131 (2), 438-439. 
125. Lacina, K.; Skládal, P., Ferroceneboronic acid for the electrochemical 
probing of interactions involving sugars. Electrochim. Acta 2011, 56. 
126. Lacina, K.; Skládal, P.; James, T. D., Boronic acids for sensing and other 
applications - a mini-review of papers published in 2013. Chemistry Central 
Journal 2014, 8 (1), 60. 
127. Wu, X.; Li, Z.; Chen, X.-X.; Fossey, J. S.; James, T. D.; Jiang, Y.-B., 
Selective sensing of saccharides using simple boronic acids and their 




128. James, T. D.; Sandanayake, K. R. A. S.; Shinkai, S., Saccharide Sensing 
with Molecular Receptors Based on Boronic Acid. Angew. Chem., Int. Ed. Engl. 
1996, 35 (17), 1910-1922. 
129. Dieterich, D. C.; Link, A. J.; Graumann, J.; Tirrell, D. A.; Schuman, E. M., 
Selective identification of newly synthesized proteins in mammalian cells using 
bioorthogonal noncanonical amino acid tagging (BONCAT). Proc. Natl. Acad. 
Sci. U. S. A. 2006, 103 (25), 9482-9487. 
130. Gaebler, A.; Milan, R.; Straub, L.; Hoelper, D.; Kuerschner, L.; Thiele, C., 
Alkyne lipids as substrates for click chemistry-based in vitro enzymatic assays. J. 
Lipid Res. 2013, 54 (8), 2282-2290. 
131. Jao, C. Y.; Roth, M.; Welti, R.; Salic, A., Metabolic labeling and direct 
imaging of choline phospholipids in vivo. Proc. Natl. Acad. Sci. U. S. A. 2009. 
132. Lu, L.; Gao, J.; Guo, Z., Labeling Cell Surface GPIs and GPI-Anchored 
Proteins through Metabolic Engineering with Artificial Inositol Derivatives. Angew. 
Chem., Int. Ed. 2015, 54 (33), 9679-9682. 
133. Ferrier, R. J., Unsaturated carbohydrates. Part 21. A carbocyclic ring 
closure of a hex-5-enopyranoside derivative. J. Chem. Soc., Perkin Trans. 1 
1979,  (0), 1455-1458. 
134. Takahashi, H.; Kittaka, H.; Ikegami, S., Novel Synthesis of 
Enantiomerically Pure Natural Inositols and Their Diastereoisomers. The J. of 




135. Qiao, L.; Hu, Y.; Nan, F.; Powis, G.; Kozikowski, A. P., A Versatile 
Approach to PI(3,4)P2, PI(4,5)P2, and PI(3,4,5)P3 from l-(−)-Quebrachitol. Org. 
Lett. 2000, 2 (2), 115-117. 
136. Hudlicky, T.; Restrepo-Sánchez, N.; Kary, P. D.; Jaramillo-Gómez, L. M., 
A short, stereoselective synthesis of neo-inositol. Carbohydr. Res. 2000, 324 (3), 
200-203. 
137. Paul, B. J.; Martinot, T. A.; Willis, J.; Hudlicky, T., Novel O- and N-Linked 
Inositol Oligomers: A New Class of Unnatural Saccharide Mimics. Synthesis 
2001, 2001 (06), 0952-0956. 
138. Hudlicky, T.; Abboud, K. A.; Entwistle, D. A.; Fan, R.; Maurya, R.; Thorpe, 
A. J.; Bolonick, J.; Myers, B., Toluene-Dioxygenase-Mediated cis-Dihydroxylation 
of Aromatics in Enantioselective Synthesis. Iterative Glycoconjugate 
CouplingStrategy and Combinatorial Design for the Synthesis of Oligomers of 
nor-Saccharides,Inositols and Pseudosugars with Interesting Molecular 
Properties. Synthesis 1996, 1996 (07), 897-911. 
139. Sureshan, K. M.; Shashidhar, M. S.; Praveen, T.; Das, T., Regioselective 
Protection and Deprotection of Inositol Hydroxyl Groups. Chemical Reviews 
2003, 103 (11), 4477-4504. 
140. Angyal, C. L.; Angyal, S. J., 125. Cyclitols. Part II. Dipole moments of 
some cyclitol acetates. J. Chem. Soc. (Resumed) 1952,  (0), 695-697. 
141. Gigg, R.; Warren, C. D., Derivatives of 2,3,4,5,6-penta-O-benzyl-myo-




142. Hudlicky, T.; Entwistle, D. A.; Pitzer, K. K.; Thorpe, A. J., Modern Methods 
of Monosaccharide Synthesis from Non-Carbohydrate Sources. Chemical 
Reviews 1996, 96 (3), 1195-1220. 
143. Reese, C. B.; Ward, J. G., Synthesis of D-myo-inositol 1,4,5-triphosphate. 
Tetrahedron Lett. 1987, 28 (20), 2309-2312. 
144. Bruzik, K. S.; Salamończyk, G. M., Synthesis of the enantiomeric 1,4,5,6-
tetra-O-benzyl-myo inositols. Carbohydr. Res. 1989, 195 (1), 67-73. 
145. Hirata, M.; Watanabe, Y.; Ishimatsu, T.; Ikebe, T.; Kimura, Y.; Yamaguchi, 
K.; Ozaki, S.; Koga, T., Synthetic inositol trisphosphate analogs and their effects 
on phosphatase, kinase, and the release of Ca2+. J. Biol. Chem. 1989, 264 (34), 
20303-20308. 
146. Hirata, M.; Yanaga, F.; Koga, T.; Ogasawara, T.; Watanabe, Y.; Ozaki, S., 
Stereospecific recognition of inositol 1,4,5-trisphosphate analogs by the 
phosphatase, kinase, and binding proteins. J. Biol. Chem. 1990, 265 (15), 8404-
8407. 
147. Ozaki, S.; Watanabe, Y.; Ogasawara, T.; Hirata, M.; Kanematsu, T., 
Synthesis and biological properties of 2-substituted myo-inositol 1,4,5-
trisphosphate analogues directed toward affinity chromatography and 
photoaffinity labeling. Carbohydr. Res. 1992, 234 (0), 189-206. 
148. Watanabe, Y.; Hirata, M.; Ogasawara, T.; Koga, T.; Ozaki, S., Synthesis 




azidobenzoyl moieties for IP-3-affiniated protein. Bioorg. Med. Chem. Lett. 1991, 
1 (8), 399-402. 
149. Guédat, P.; Poitras, M.; Spiess, B.; Guillemette, G.; Schlewer, G., Rapid 
synthesis and properties of (±)-6-Deoxy-6-fluoro-myo-inositol-1,4,5-
tris(phosphate) an analogue of myo-inositol-1,4,5-tris(phosphate). Bioorg. Med. 
Chem. Lett. 1996, 6 (10), 1175-1178. 
150. Bruzik, K. S.; Tsai, M. D., Efficient and systematic syntheses of 
enantiomerically pure and regiospecifically protected myo-inositols. J. Am. Chem. 
Soc. 1992, 114 (16), 6361-6374. 
151. Vinod, T. K.; Hayes Griffith, O.; Keana, J. F. W., Synthesis of isosteric and 
isopolar phosphonate substrate analogues designed as inhibitors for 
phosphatidylinositol-specific phospholipase C from bacillus cereus. Tetrahedron 
Lett. 1994, 35 (39), 7193-7196. 
152. Bruzik, K. S.; Myers, J.; Tsai, M.-D., Practical synthesis of 
enantiomerically pure myo-inositol derivatives. Tetrahedron Lett. 1992, 33 (8), 
1009-1012. 
153. Salamończyk, G. M.; Pietrusiewicz, K. M., Synthesis of enantiomerically 
pure D-myo-inositol 1,5,6-triphosphate. Tetrahedron Lett. 1994, 35 (24), 4233-
4234. 
154. Salamończyk, G. M.; Pietrusiewicz, K. M., Expedient synthesis of D - myo 
- inositol 1,4,5 - trisphosphate and D - myo - inositol 1,4 - bisphosphate. 




155. Biamonte, M. A.; Vasella, A., Glycosylidene Carbenes part 26. The 
intramolecular F…︁HO hydrogen bond of 1,3-diaxial 3-fluorocyclohexanols. 
Helv. Chim. Acta 1998, 81 (3-4), 695-717. 
156. Chung, M.-K.; Orlova, G.; Goddard, J. D.; Schlaf, M.; Harris, R.; 
Beveridge, T. J.; White, G.; Hallett, F. R., Regioselective Silylation of Sugars 
through Palladium Nanoparticle-Catalyzed Silane Alcoholysis. J. Am. Chem. Soc. 
2002, 124 (35), 10508-10518. 
157. Li, C.; Vasella, A., A New Synthesis of Benzylidene Acetals. Helv. Chim. 
Acta 1993, 76 (1), 211-221. 
158. Dawson, J. P.; Weinger, J. S.; Engelman, D. M., Motifs of serine and 
threonine can drive association of transmembrane helices1. J. Mol. Biol. 2002, 
316 (3), 799-805. 
159. Stauffer, G., Regulation of Serine, Glycine, and One-Carbon Biosynthesis. 
EcoSal Plus 2004. 
160. Hedstrom, L., Serine Protease Mechanism and Specificity. Chemical 
Reviews 2002, 102 (12), 4501-4524. 
161. Vance, J. E.; Steenbergen, R., Metabolism and functions of 
phosphatidylserine. Prog. Lipid Res. 2005, 44 (4), 207-234. 
162. Sinn, C. G.; Antonietti, M.; Dimova, R., Binding of calcium to 





163. Martín-Molina, A.; Rodríguez-Beas, C.; Faraudo, J., Effect of Calcium and 
Magnesium on Phosphatidylserine Membranes: Experiments and All-Atomic 
Simulations. Biophys. J. 2012, 102 (9), 2095-2103. 
164. Tait, J. F.; Gibson, D., Phospholipid binding of annexin V: Effects of 
calcium and membrane phosphatidylserine content. Arch. Biochem. Biophys. 
1992, 298 (1), 187-191. 
165. Kanfer, J.; Kennedy, E. P., Metabolism and Function of Bacterial Lipids: II. 
Biosynthesis of Phospholipids in Escherichia Coli. J. Biol. Chem. 1964, 239 (6), 
1720-1726. 
166. Matsumoto, K., Phosphatidylserine synthase from bacteria. Biochim. 
Biophys. Acta, Lipids and Lipid Metab. 1997, 1348 (1), 214-227. 
167. Zhang, Y.-M.; Rock, C. O., Membrane lipid homeostasis in bacteria. Nat 
Rev Micro 2008, 6 (3), 222-233. 
168. Nikawa, J.-I.; Yamashita, S., Characterization of phosphatidylserine 
synthase from saccharomyces cerevisiae and a mutant defective in the enzyme. 
Biochim. Biophys. Acta, Lipids and Lipid Metab. 1981, 665 (3), 420-426. 
169. Atkinson, K.; Fogel, S.; Henry, S. A., Yeast mutant defective in 
phosphatidylserine synthesis. J. Biol. Chem. 1980, 255 (14), 6653-61. 
170. Chen, Y.-L.; Montedonico, A. E.; Kauffman, S.; Dunlap, J. R.; Menn, F.-M.; 
Reynolds, T. B., Phosphatidylserine synthase and phosphatidylserine 
decarboxylase are essential for cell wall integrity and virulence in Candida 




171. Davis, S. E.; Hopke, A.; Minkin, S. C.; Montedonico, A. E.; Wheeler, R. T.; 
Reynolds, T. B., Masking of β(1-3)-Glucan in the Cell Wall of Candida albicans 
from Detection by Innate Immune Cells Depends on Phosphatidylserine. Infect. 
Immun. 2014, 82 (10), 4405-4413. 
172. Wolf, J. M.; Espadas, J.; Luque-Garcia, J.; Reynolds, T.; Casadevall, A., 
Lipid Biosynthetic Genes Affect Candida albicans Extracellular Vesicle 
Morphology, Cargo, and Immunostimulatory Properties. Eukaryotic Cell 2015, 14 
(8), 745-754. 
173. Vance, J. E.; Tasseva, G., Formation and function of phosphatidylserine 
and phosphatidylethanolamine in mammalian cells. Biochim. Biophys. Acta, Mol. 
and Cell Bio. of Lipids 2013, 1831 (3), 543-554. 
174. Linde, K.; Gröbner, G.; Rilfors, L., Lipid dependence and activity control of 
phosphatidylserine synthase from Escherichia coli. FEBS Lett. 2004, 575 (1-3), 
77-80. 
175. Rilfors, L.; Niemi, A.; Haraldsson, S.; Edwards, K.; Andersson, A.-S.; 
Dowhan, W., Reconstituted phosphatidylserine synthase from Escherichia coli is 
activated by anionic phospholipids and micelle-forming amphiphiles. Biochim. 
Biophys. Acta, Mol. and Cell Bio. of Lipids 1999, 1438 (2), 281-294. 
176. Kuchler, K.; Daum, G.; Paltauf, F., Subcellular and submitochondrial 
localization of phospholipid-synthesizing enzymes in Saccharomyces cerevisiae. 




177. Kohlwein, S. D.; Kuchler, K.; Sperka-Gottlieb, C.; Henry, S. A.; Paltauf, F., 
Identification of mitochondrial and microsomal phosphatidylserine synthase in 
Saccharomyces cerevisiae as the gene product of the CHO1 structural gene. J. 
Bacteriol. 1988, 170 (8), 3778-3781. 
178. Kodaki, T.; Nikawa, J.; Hosaka, K.; Yamashita, S., Functional analysis of 
the regulatory region of the yeast phosphatidylserine synthase gene, PSS. J. 
Bacteriol. 1991, 173 (24), 7992-7995. 
179. Carman, G. M.; Kersting, M. C., Phospholipid synthesis in yeast: 
regulation by phosphorylation. Biochem. Cell Biol. 2004, 82 (1), 62-70. 
180. Jesch, S. A.; Zhao, X.; Wells, M. T.; Henry, S. A., Genome-wide Analysis 
Reveals Inositol, Not Choline, as the Major Effector of Ino2p-Ino4p and Unfolded 
Protein Response Target Gene Expression in Yeast. J. Biol. Chem. 2005, 280 
(10), 9106-9118. 
181. Kinney, A. J.; Carman, G. M., Phosphorylation of yeast phosphatidylserine 
synthase in vivo and in vitro by cyclic AMP-dependent protein kinase. Proc. Natl. 
Acad. Sci. 1988, 85 (21), 7962-7966. 
182. Iwanyshyn, W. M.; Han, G.-S.; Carman, G. M., Regulation of Phospholipid 
Synthesis in Saccharomyces cerevisiae by Zinc. J. Biol. Chem. 2004, 279 (21), 
21976-21983. 
183. Zinser, E.; Sperka-Gottlieb, C. D.; Fasch, E. V.; Kohlwein, S. D.; Paltauf, 




membranes in the unicellular eukaryote Saccharomyces cerevisiae. J. Bacteriol. 
1991, 173 (6), 2026-2034. 
184. Bretscher, M. S., Membrane Structure: Some General Principles. Science 
1973, 181 (4100), 622. 
185. Zborowski, J.; Dygas, A.; Wojtczak, L., Phosphatidylserine decarboxylase 
is located on the external side of the inner mitochondrial membrane. FEBS Lett. 
1983, 157 (1), 179-182. 
186. McEvoy, L.; Williamson, P.; Schlegel, R. A., Membrane phospholipid 
asymmetry as a determinant of erythrocyte recognition by macrophages. Proc. 
Natl. Acad. Sci. U. S. A. 1986, 83 (10), 3311-3315. 
187. Verhoven, B.; Schlegel, R. A.; Williamson, P., Mechanisms of 
phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T 
lymphocytes. The J. Exp. Med. 1995, 182 (5), 1597-1601. 
188. Fadok, V. A.; Voelker, D. R.; Campbell, P. A.; Cohen, J. J.; Bratton, D. L.; 
Henson, P. M., Exposure of phosphatidylserine on the surface of apoptotic 
lymphocytes triggers specific recognition and removal by macrophages. The J. 
Immunol. 1992, 148 (7), 2207-2216. 
189. Martin, S. J.; Finucane, D. M.; Amarante-Mendes, G. P.; O'Brien, G. A.; 
Green, D. R., Phosphatidylserine Externalization during CD95-induced Apoptosis 
of Cells and Cytoplasts Requires ICE/CED-3 Protease Activity. J. Biol. Chem. 




190. Martin, S. J.; Reutelingsperger, C. P.; McGahon, A. J.; Rader, J. A.; van 
Schie, R. C.; LaFace, D. M.; Green, D. R., Early redistribution of plasma 
membrane phosphatidylserine is a general feature of apoptosis regardless of the 
initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. The J. Exp. Med. 
1995, 182 (5), 1545-1556. 
191. Aussel, C.; Pelassy, C.; Breittmayer, J. P., CD95 (Fas/APO-1) induces an 
increased phosphatidylserine synthesis that precedes its externalization during 
programmed cell death. FEBS Lett. 1998, 431 (2), 195-199. 
192. Yu, A.; Byers, D. M.; Ridgway, N. D.; McMaster, C. R.; Cook, H. W., 
Preferential externalization of newly synthesized phosphatidylserine in apoptotic 
U937 cells is dependent on caspase-mediated pathways. Biochim. Biophys. 
Acta, Mol. and Cell Bio. of Lipids 2000, 1487 (2–3), 296-308. 
193. Miyanishi, M.; Tada, K.; Koike, M.; Uchiyama, Y.; Kitamura, T.; Nagata, S., 
Identification of Tim4 as a phosphatidylserine receptor. Nature 2007, 450 (7168), 
435-439. 
194. Hanayama, R.; Tanaka, M.; Miwa, K.; Shinohara, A.; Iwamatsu, A.; 
Nagata, S., Identification of a factor that links apoptotic cells to phagocytes. 
Nature 2002, 417 (6885), 182-187. 
195. Maiti, S. N.; Balasubramanian, K.; Ramoth, J. A.; Schroit, A. J., β-2-
Glycoprotein 1-dependent Macrophage Uptake of Apoptotic Cells: Binding to 
Lipoprotein Receptor-Related Protein Receptor Family Members. J. Biol. Chem. 




196. Fan, X.; Krahling, S.; Smith, D.; Williamson, P.; Schlegel, R. A., 
Macrophage Surface Expression of Annexins I and II in the Phagocytosis of 
Apoptotic Lymphocytes. Mol. Biol. Cell 2004, 15 (6), 2863-2872. 
197. Gerke, V.; Moss, S. E., Annexins: From Structure to Function. Physiol. 
Rev. 2002, 82 (2), 331-371. 
198. Bevers, E. M.; Williamson, P. L., Getting to the Outer Leaflet: Physiology 
of Phosphatidylserine Exposure at the Plasma Membrane. Physiol. Rev. 2016, 
96 (2), 605-645. 
199. Lahorte, C. M. M.; Vanderheyden, J.-L.; Steinmetz, N.; Van de Wiele, C.; 
Dierckx, R. A.; Slegers, G., Apoptosis-detecting radioligands: current state of the 
art and future perspectives. Eur. J. Nuc. Med. and Mol. Imag. 2004, 31 (6), 887-
919. 
200. Eckelman, W. C.; Steigman, J., Direct labeling with 99mTc. Int. J. Radiat. 
App. and Instr. Part B. Nuc. Med. and Biol. 18 (1), 3-7. 
201. Kemerink, G. J.; Liem, I. H.; Hofstra, L.; Boersma, H. H.; Buijs, W. C. A. 
M.; Reutelingsperger, C. P. M.; Heidendal, G. A. K., Patient Dosimetry of 
Intravenously Administered 99mTc-Annexin V. J Nucl Med 2001, 42 (2), 382-
387. 
202. Yang, D. J.; Azhdarinia, A.; Wu, P.; Yu, D.-F.; Tansey, W.; Kalimi, S. K.; 
Kim, E. E.; Podoloff, D. A., In Vivo and In Vitro Measurement of Apoptosis in 
Breast Cancer Cells Using 99mTc-EC-Annexin V. Cancer Biotherapy and 




203. Tait, J. F.; Cerqueira, M. D.; Dewhurst, T. A.; Fujikawa, K.; Ritchie, J. L.; 
Stratton, J. R., Evaluation of annexin V as a platelet-directed thrombus targeting 
agent. Thromb. Res. 1994, 75 (5), 491-501. 
204. Russell, J.; O’Donoghue, J. A.; Finn, R.; Koziorowski, J.; Ruan, S.; Humm, 
J. L.; Ling, C. C., Iodination of Annexin V for Imaging Apoptosis. J Nucl Med 
2002, 43 (5), 671-677. 
205. Lahorte, C. M. M.; Van De Wiele, C.; Bacher, K.; Van Den Bossche, B.; 
Thierens, H.; Van Belle, S.; Slegers, G.; Dierckx, R. A., Biodistribution and 
dosimetry study of 123I‐rh‐annexin V in mice and humans. Nucl Med Commun 
2003, 24 (8), 871-880. 
206. Zijlstra, S.; Gunawan, J.; Burchert, W., Synthesis and evaluation of a 18F-
labelled recombinant annexin-V derivative, for identification and quantification of 
apoptotic cells with PET. Appl. Radiat. Isot. 2003, 58 (2), 201-207. 
207. Wen, X.; Wu, Q.-P.; Ke, S.; Wallace, S.; Charnsangavej, C.; Huang, P.; 
Liang, D.; Chow, D.; Li, C., Improved Radiolabeling of PEGylated Protein: 
PEGylated Annexin V for Noninvasive Imaging of Tumor Apoptosis. Cancer 
Biotherapy and Radiopharmaceuticals 2003, 18 (5), 819-827. 
208. Strebel, A.; Harr, T.; Bachmann, F.; Wernli, M.; Erb, P., Green fluorescent 
protein as a novel tool to measure apoptosis and necrosis. Cytometry 2001, 43 
(2), 126-133. 
209. Lee, S. H.; Meng, X. W.; Flatten, K. S.; Loegering, D. A.; Kaufmann, S. H., 




between plasma membrane and cytoplasm. Cell Death Differ 2013, 20 (1), 64-
76. 
210. Bouchier-Hayes, L.; Muñoz-Pinedo, C.; Connell, S.; Green, D. R., 
Measuring apoptosis at the single cell level. Methods 2008, 44 (3), 222-228. 
211. Gurale, B. P.; Shashidhar, M. S.; Gonnade, R. G., Synthesis of the 
Aminocyclitol Units of (−)-Hygromycin A and Methoxyhygromycin from myo-
Inositol. J. Org. Chem. 2012, 77 (13), 5801-5807. 
212. Lauber, M. B.; Daniliuc, C.-G.; Paradies, J., Desymmetrization of 4,6-
diprotected myo-inositol. Chem. Commun. 2013, 49 (67), 7409-7411. 
213. Jiang, G.; Xu, Y.; Falguières, T.; Gruenberg, J.; Prestwich, G. D., Concise 
Synthesis of Ether Analogues of Lysobisphosphatidic Acid. Org. Lett. 2005, 7 
(18), 3837-3840. 
214. Niemietz, M.; Perkams, L.; Hoffman, J.; Eller, S.; Unverzagt, C., Selective 
oxidative debenzylation of mono- and oligosaccharides in the presence of azides. 
Chem. Commun. 2011, 47 (37), 10485-10487. 
215. Breidenbach, M. A.; Gallagher, J. E. G.; King, D. S.; Smart, B. P.; Wu, P.; 
Bertozzi, C. R., Targeted metabolic labeling of yeast N-glycans with unnatural 
sugars. Proc. Natl. Acad. Sci. 2010, 107 (9), 3988-3993. 
216. Dickson, R. C.; Lester, R. L., Yeast sphingolipids. Biochimica et 




217. Cowart, L. A.; Obeid, L. M., Yeast sphingolipids: Recent developments in 
understanding biosynthesis, regulation, and function. Biochim. Biophys. Acta, 
Mol. and Cell Bio. of Lipids 2007, 1771 (3), 421-431. 
218. Noritaka, C.; Keiichi, N.; Masami, O.; Minoru, S.; Seiichiro, O., Total 
Synthesis of Methoxyhygromycin and Its 5-Epimer. Chem. Lett. 1990, 19 (3), 
423-426. 
219. Ravi, A.; Hassan, S. Z.; Vanikrishna, A. N.; Sureshan, K. M., 
Regioselective SN2 reactions for rapid syntheses of azido-inositols by one-pot 
sequence-specific nucleophilysis. Chem. Commun. 2017, 53 (28), 3971-3973. 
220. Lee, N.-Y.; Jang, W.-J.; Yu, S.-H.; Im, J.; Chung, S.-K., Syntheses of 
glycodendrimers having scyllo-inositol as the scaffold. Tetrahedron Lett. 2005, 46 
(36), 6063-6066. 
221. Botstein, D.; Chervitz, S. A.; Cherry, M., Yeast as a Model Organism. 
Science 1997, 277 (5330), 1259-1260. 
222. Mandala, S. M.; Thornton, R. A.; Rosenbach, M.; Milligan, J.; Garcia-
Calvo, M.; Bull, H. G.; Kurtz, M. B., Khafrefungin, a Novel Inhibitor of Sphingolipid 
Synthesis. J. Biol. Chem. 1997, 272 (51), 32709-32714. 
223. Nagiec, M. M.; Nagiec, E. E.; Baltisberger, J. A.; Wells, G. B.; Lester, R. 
L.; Dickson, R. C., Sphingolipid Synthesis as a Target for Antifungal Drugs: 
Complementation of the Inositol Phosphorylceramide Synthase Defect in a 
Mutant Strain of Saccharomyces Cerevisiae by the AUR1 Gene. J. Biol. Chem. 




224. Peña, A.; Uribe, S.; Pardo, J. P.; Borbolla, M., The use of a cyanine dye in 
measuring membrane potential in yeast. Arch. Biochem. Biophys. 1984, 231 (1), 
217-225. 
225. Lloyd, D.; Moran, C. A.; Suller, M. T. E.; Dinsdale, M. G.; Hayes, A. J., 
Flow Cytometric Monitoring of Rhodamine 123 and a Cyanine Dye Uptake by 
Yeast During Cider Fermentation. J. Inst. Brew. 1996, 102 (4), 251-259. 
226. Guan, X. L.; Wenk, M. R., Mass spectrometry-based profiling of 
phospholipids and sphingolipids in extracts from Saccharomyces cerevisiae. 
Yeast 2006, 23 (6), 465-477. 
227. Wenk, M. R.; Lucast, L.; Di Paolo, G.; Romanelli, A. J.; Suchy, S. F.; 
Nussbaum, R. L.; Cline, G. W.; Shulman, G. I.; McMurray, W.; De Camilli, P., 
Phosphoinositide profiling in complex lipid mixtures using   electrospray 
ionization mass spectrometry. Nat Biotech 2003, 21 (7), 813-817. 
228. Gonzalez-Sastre, F.; Folch-Pi, J., Thin-layer chromatography of the 
phosphoinositides. J. Lipid Res. 1968, 9 (4), 532-533. 
229. König, S.; Hoffmann, M.; Mosblech, A.; Heilmann, I., Determination of 
content and fatty acid composition of unlabeled phosphoinositide species by thin-
layer chromatography and gas chromatography. Anal. Biochem. 2008, 378 (2), 
197-201. 
230. Cravatt, B. F.; Wright, A. T.; Kozarich, J. W., Activity-Based Protein 
Profiling: From Enzyme Chemistry to Proteomic Chemistry. Annu. Rev. Biochem. 




231. Broderick, J. B., Coenzymes and Cofactors. In eLS, John Wiley & Sons, 
Ltd: 2001. 
232. Fiore, M.; Lo Conte, M.; Pacifico, S.; Marra, A.; Dondoni, A., Synthesis of 
S-glycosyl amino acids and S-glycopeptides via photoinduced click thiol–ene 
coupling. Tetrahedron Lett. 2011, 52 (3), 444-447. 
233. Kenworthy, M. N.; Kilburn, J. P.; Taylor, R. J. K., Highly Functionalized 
Organolithium Reagents for Enantiomerically Pure α-Amino Acid Synthesis. Org. 
Lett. 2004, 6 (1), 19-22. 
234. Yang, Y.-Y.; Grammel, M.; Raghavan, A. S.; Charron, G.; Hang, H. C., 
Comparative Analysis of Cleavable Azobenzene-Based Affinity Tags for 
Bioorthogonal Chemical Proteomics. Chem. Biol. 2010, 17 (11), 1212-1222. 
235. Hicks, M. R.; Rullay, A. K.; Pedrido, R.; Crout, D. H.; Pinheiro, T. J. T., 
Efficient Synthesis of Methanesulphonate-Derived Lipid Chains for Attachment of 
Proteins to Lipid Membranes. Synth. Commun. 2008, 38 (21), 3726-3750. 
236. Walter, M.; Wiegand, M.; Lindhorst, T. K., Synthesis of Cluster 
Mannosides Carrying a Photolabile Diazirine Group. Eur. J. Org. Chem. 2006, 
2006 (3), 719-728. 
237. Niemi, R. M.; Vepsäläinen, M., Stability of the fluorogenic enzyme 
substrates and pH optima of enzyme activities in different Finnish soils. J 
Microbiol Methods 2005, 60 (2), 195-205. 
238. Manafi, M., Fluorogenic and chromogenic enzyme substrates in culture 




239. Schilling, E. A.; Kamholz, A. E.; Yager, P., Cell Lysis and Protein 
Extraction in a Microfluidic Device with Detection by a Fluorogenic Enzyme 
Assay. Anal. Chem. 2002, 74 (8), 1798-1804. 
240. Munishkina, L. A.; Fink, A. L., Fluorescence as a method to reveal 
structures and membrane-interactions of amyloidogenic proteins. Biochimica et 
Biophysica Acta (BBA) - Biomembranes 2007, 1768 (8), 1862-1885. 
241. Ghisaidoobe, A.; Chung, S., Intrinsic Tryptophan Fluorescence in the 
Detection and Analysis of Proteins: A Focus on Förster Resonance Energy 
Transfer Techniques. International Journal of Molecular Sciences 2014, 15 (12), 
22518. 
242. Redy-Keisar, O.; Ferber, S.; Satchi-Fainaro, R.; Shabat, D., NIR 
Fluorogenic Dye as a Modular Platform for Prodrug Assembly: Real-Time in vivo 
Monitoring of Drug Release. ChemMedChem 2015, 10 (6), 999-1007. 
243. Wu, H.; Alexander, S. C.; Jin, S.; Devaraj, N. K., A Bioorthogonal Near-
Infrared Fluorogenic Probe for mRNA Detection. J. Am. Chem. Soc. 2016, 138 
(36), 11429-11432. 
244. Shieh, P.; Siegrist, M. S.; Cullen, A. J.; Bertozzi, C. R., Imaging bacterial 
peptidoglycan with near-infrared fluorogenic azide probes. Proc. Natl. Acad. Sci. 
2014, 111 (15), 5456-5461. 
245. Koide, Y.; Urano, Y.; Hanaoka, K.; Terai, T.; Nagano, T., Evolution of 
Group 14 Rhodamines as Platforms for Near-Infrared Fluorescence Probes 




246. Fu, M.; Xiao, Y.; Qian, X.; Zhao, D.; Xu, Y., A design concept of long-
wavelength fluorescent analogs of rhodamine dyes: replacement of oxygen with 
silicon atom. Chem. Commun. 2008,  (15), 1780-1782. 
247. Egawa, T.; Koide, Y.; Hanaoka, K.; Komatsu, T.; Terai, T.; Nagano, T., 
Development of a fluorescein analogue, TokyoMagenta, as a novel scaffold for 
fluorescence probes in red region. Chem. Commun. 2011, 47 (14), 4162-4164. 
248. Reshetnyak, Y. K.; Andreev, O. A.; Lehnert, U.; Engelman, D. M., 
Translocation of molecules into cells by pH-dependent insertion of a 
transmembrane helix. Proc. Natl. Acad. Sci. 2006, 103 (17), 6460-6465. 
249. Andreev, O. A.; Dupuy, A. D.; Segala, M.; Sandugu, S.; Serra, D. A.; 
Chichester, C. O.; Engelman, D. M.; Reshetnyak, Y. K., Mechanism and uses of 
a membrane peptide that targets tumors and other acidic tissues in vivo. Proc. 
Natl. Acad. Sci. 2007, 104 (19), 7893-7898. 
250. Zoonens, M.; Reshetnyak, Y. K.; Engelman, D. M., Bilayer Interactions of 
pHLIP, a Peptide that Can Deliver Drugs and Target Tumors. Biophys. J. 2008, 
95 (1), 225-235. 
251. Andreev, O. A.; Engelman, D. M.; Reshetnyak, Y. K., Targeting acidic 
diseased tissue: New technology based on use of the pH (Low) Insertion Peptide 
(pHLIP). Chim Oggi 2009, 27 (2), 34-37. 
252. Andreev, O. A.; Engelman, D. M.; Reshetnyak, Y. K., pH-sensitive 
membrane peptides (pHLIPs) as a novel class of delivery agents. Mol. Membr. 




253. Daumar, P.; Wanger-Baumann, C. A.; Pillarsetty, N.; Fabrizio, L.; Carlin, 
S. D.; Andreev, O. A.; Reshetnyak, Y. K.; Lewis, J. S., Efficient 18F-Labeling of 
Large 37-Amino-Acid pHLIP Peptide Analogues and Their Biological Evaluation. 
Bioconjugate Chem. 2012, 23 (8), 1557-1566. 
254. Karabadzhak, A. G.; An, M.; Yao, L.; Langenbacher, R.; Moshnikova, A.; 
Adochite, R.-C.; Andreev, O. A.; Reshetnyak, Y. K.; Engelman, D. M., pHLIP-
FIRE, a Cell Insertion-Triggered Fluorescent Probe for Imaging Tumors 
Demonstrates Targeted Cargo Delivery In Vivo. ACS Chem. Biol. 2014, 9 (11), 
2545-2553. 
255. Wyatt, L. C.; Lewis, J. S.; Andreev, O. A.; Reshetnyak, Y. K.; Engelman, 
D. M., Applications of pHLIP Technology for Cancer Imaging and Therapy. 
Trends Biotechnol. 2017. 
256. Hunt, J. F.; Rath, P.; Rothschild, K. J.; Engelman, D. M., Spontaneous, 
pH-Dependent Membrane Insertion of a Transbilayer α-Helix. Biochemistry 1997, 
36 (49), 15177-15192. 
257. Miller, D. S.; Chirayil, S.; Ball, H. L.; Luebke, K. J., Manipulating Cell 
Migration and Proliferation with a Light-Activated Polypeptide. ChemBioChem 
2009, 10 (3), 577-584. 
258. McGall, G. H.; Barone, A. D.; Diggelmann, M.; Fodor, S. P. A.; Gentalen, 
E.; Ngo, N., The Efficiency of Light-Directed Synthesis of DNA Arrays on Glass 




259. Pastierik, T.; Šebej, P.; Medalová, J.; Štacko, P.; Klán, P., Near-Infrared 
Fluorescent 9-Phenylethynylpyronin Analogues for Bioimaging. The J. of Org. 


























































































































































































































 Tanei J. Ricks was born on April 21, 1986 in Augusta, GA to Mr. Joe Ricks 
and Ms. Almeca Simms. He graduated from Augusta State University in May 
2012 with a B.S. in Chemistry with a focus in Biochemistry. In August of 2012, he 
entered the Chemistry doctoral program at the University of Tennessee-
Knoxville. 
